EP0300796A2 - Amplification method for polynucleotide assays - Google Patents
Amplification method for polynucleotide assays Download PDFInfo
- Publication number
- EP0300796A2 EP0300796A2 EP88306717A EP88306717A EP0300796A2 EP 0300796 A2 EP0300796 A2 EP 0300796A2 EP 88306717 A EP88306717 A EP 88306717A EP 88306717 A EP88306717 A EP 88306717A EP 0300796 A2 EP0300796 A2 EP 0300796A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polynucleotide
- sequence
- template
- fragments
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 446
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 446
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 446
- 238000000034 method Methods 0.000 title claims abstract description 127
- 230000003321 amplification Effects 0.000 title description 16
- 238000003199 nucleic acid amplification method Methods 0.000 title description 16
- 238000003556 assay Methods 0.000 title description 11
- 239000012634 fragment Substances 0.000 claims abstract description 100
- 239000012491 analyte Substances 0.000 claims abstract description 89
- 230000001419 dependent effect Effects 0.000 claims abstract description 49
- 239000001226 triphosphate Substances 0.000 claims abstract description 42
- 235000011178 triphosphate Nutrition 0.000 claims abstract description 42
- -1 nucleoside triphosphates Chemical class 0.000 claims abstract description 32
- 239000002777 nucleoside Substances 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 108020004414 DNA Proteins 0.000 claims description 76
- 239000002773 nucleotide Substances 0.000 claims description 71
- 230000000295 complement effect Effects 0.000 claims description 69
- 125000003729 nucleotide group Chemical group 0.000 claims description 69
- 238000003776 cleavage reaction Methods 0.000 claims description 68
- 230000007017 scission Effects 0.000 claims description 68
- 108091008146 restriction endonucleases Proteins 0.000 claims description 55
- 239000003153 chemical reaction reagent Substances 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 239000013615 primer Substances 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 20
- 102000053602 DNA Human genes 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 17
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 238000006116 polymerization reaction Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000004925 denaturation Methods 0.000 claims description 10
- 230000036425 denaturation Effects 0.000 claims description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 7
- 125000006853 reporter group Chemical group 0.000 claims description 7
- 239000003155 DNA primer Substances 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 238000012197 amplification kit Methods 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 15
- 239000000523 sample Substances 0.000 description 41
- 239000002585 base Substances 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- 229920002477 rna polymer Polymers 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 19
- 239000000872 buffer Substances 0.000 description 15
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 14
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 14
- 238000007792 addition Methods 0.000 description 11
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 11
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 8
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 8
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 8
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 238000007899 nucleic acid hybridization Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 241000726445 Viroids Species 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002429 hydrazines Chemical class 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 108010064978 Type II Site-Specific Deoxyribonucleases Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960004319 trichloroacetic acid Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000000823 Polynucleotide Ligases Human genes 0.000 description 1
- 108010001797 Polynucleotide Ligases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108010027697 Type I Site-Specific Deoxyribonucleases Proteins 0.000 description 1
- 108010067022 Type III Site-Specific Deoxyribonucleases Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QEUYATCJHJUQML-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 QEUYATCJHJUQML-UHFFFAOYSA-N 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 229940002707 acriflavine hydrochloride Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940048195 n-(hydroxyethyl)ethylenediaminetriacetic acid Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Definitions
- Nucleic acid hybridization has been employed for investigating the identity and establishing the presence of nucleic acids. Hybridization is based on complementary base pairing. When complementary single stranded nucleic acids are incubated together, the complementary base sequences pair to form double stranded hybrid molecules.
- ssDNA single stranded deoxyribonucleic acid
- RNA ribonucleic acid
- the availability of radioactive nucleoside triphosphates of high specific activity and the 32P labelling of DNA with T4 kinase has made it possible to identify, isolate, and characterize various nucleic acid sequences of biological interest.
- Nucleic acid hybridization has great potential in diagnosing disease states associated with unique nucleic acid sequences. These unique nucleic acid sequences may result from genetic or environmental change in DNA by insertions, deletions, point mutations, or by acquiring foreign DNA or RNA by means of infection by bacteria, molds, fungi, and viruses. Nucleic acid hybridization has, until now, been employed primarily in academic and industrial molecular biology laboratories. The application of nucleic acid hybridization as a diagnostic tool in clinical medicine is limited because of the frequently very low concentrations of disease related DNA or RNA present in a patient's body fluid and the unavailability of a sufficiently sensitive method of nucleic acid hybridization analysis.
- detecting specific nucleic acid sequences generally involve immobilization of the target nucleic acid on a solid support such as nitrocellulose paper, cellulose paper, diazotized paper, or a nylon membrane. After the target nucleic acid is fixed on the support, the support is contacted with a suitably labelled probe nucleic acid for about two to forty-eight hours. After the above time period, the solid support is washed several times at a controlled temperature to remove unhybridized probe. The support is then dried and the hybridized material is detected by autoradiography or by spectrometric methods.
- a solid support such as nitrocellulose paper, cellulose paper, diazotized paper, or a nylon membrane.
- PCR polymerase chain reaction
- a process for amplifying, detecting and/or cloning nucleic acid sequences is disclosed in European Patent Applications 0 200 362 and 0 201 184. Sequence polymerization by polymerase chain reaction is described by Saiki, et al ., (1986) Science , 230 : 1350-1354. A method of making an oligonucleotide is described in European Patent Application No. 0194545. Belgian Patent No. 904402 discloses a mold for making DNA detection probes. Gene amplification in eukaryotic cells is disclosed in U.S. Patent No. 4,656,134.
- U.S. Patent No. 4,480,040 discloses the sensitive and rapid diagnosis of plant viroid diseases and viruses employing radioactively labelled DNA that is complementary to the viroid or to the nucleic acid of the virus being diagnosed.
- European Patent Application 97373 (83106112.2) (Priority U.S. Patent Application 391,440 filed June 23, 1982) teaches modified labelled nucleotides and polynucleotides and methods of preparing, utilizing, and detecting the same. Methods and compositions for the detection and determination of cellular DNA are disclosed in U.S. Patent No. 4,423,153. Specific DNA probes in diagnostic microbiology are discussed in U.S. Patent No. 4,358,535. A method for detection of polymorphic restriction sites and nucleic acid sequences is discussed in European Patent Application No. 0164054.
- U.S. Patent No. 4,663,283 describes a method of altering double-stranded DNA.
- the invention disclosed herein includes methods and reagents for producing multiple copies of a primary polynucleotide sequence. This process can be initiated by the presence of a target polynucleotide sequence located at the 3′ terminus of a polynucleotide.
- the method comprises: (a) forming in the presence of nucleoside triphosphates and template-dependent polynucleotide polymerase an extension of a primary polynucleotide sequence hybridized with a template sequence of a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more cleavable sites (such as site specific cleavage sequences), (b) cleaving into fragments the extension at cleavable sites (such as polynucleotide sequences) in the presence of means for specifically cleaving the cleavable sites (such as polynucleotide sequences) when the extension is hybridized with the template sequence (for example with site specific cleavage sequences therein), (c) dissociating the fragments, (d) hybridizing the fragments with single stranded pattern polynucleotide, and repeating steps (a)-(d) above. Steps (a)-(d) can be conducted simultaneously or wholly
- the method and reagents have application in facilitating the determination of the presence of a polynucleotide analyte containing a target polynucleotide sequence in a sample suspected of containing such polynucleotide analyte.
- the target polynucleotide sequence can be DNA or RNA.
- the target sequence is cut, e.g., by enzymes to provide a free 3′-OH when it does not already terminate in a 3′-OH.
- the target sequence is dissociated from any complementary nucleic acid and hybridized to a complementary binding sequence located at the 3′ end of two or more template sequences in the single stranded pattern polynucleotide.
- Chain extension of the target sequence with nucleoside triphosphates and template dependent polynucleotide polymerase and cleavage of the cleavable polynucleotide sequence in the extension provides the primary polynucleotide sequences in this invention.
- compositions for carrying out the above methods are a single stranded pattern polynucleotide that comprises an oligomer consisting of three to one-thousand monomeric units each consisting of an oligonucleotide template having from about eight to one-hundred bases and at least one restriction site.
- the monomeric units are preferably but need not be identical.
- the oligomer may be substituted at the 3′-end with a binding sequence complementary to a target sequence, and the 3′-terminal nucleotide will preferably be substituted by a chemical functionality that prevents a chain extension reaction with a template dependent polynucleotide polymerase.
- the single stranded pattern polynucleotide may be a ring.
- the cleaved fragments are detected by any means for detecting DNA fragments. The presence of the fragment or a complementary fragment indicates the presence of the polynucleotide analyte in the sample.
- the present method allows the production of multiple copies of a primary polynucleotide sequence.
- the formation of the primary polynucleotide sequence can be initiated by the presence of a target polynucleotide sequence located at the 3′-terminus of a polynucleotide and is useful in detection of such a target sequence.
- the target polynucleotide sequence may be present in a polynucleotide analyte in a sample suspected of containing the analyte.
- the primary polynucleotide sequence may be the same as, but is preferably different from, the target polynucleotide sequence.
- the following components are provided: (i) the primary polynucleotide sequence, (ii) a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more site specific cleavage sequences, (iii) nucleoside triphosphates, (iv) template-dependent polynucleotide polymerase, and (v) means for specifically cleaving cleavable polynucleotide sequences when an extension of the primary polynucleotide sequence is hybridized with the site specific cleavage sequences.
- the template sequence is complementary to and can hybridize with the primary polynucleotide sequence.
- the complex of the primary polynucleotide sequence with the single stranded pattern polynucleotide is incubated either simultaneously or wholly or partially sequentially with remaining components under conditions for either simultaneously or wholly or partially sequentially forming the extension of the primary polynucleotide sequence comprising one or more copies of the primary polynucleotide sequence connected through the cleavable polynucleotide sequences, cleaving the extension into fragments at the cleavable polynucleotide sequences, dissociating the complex of the template sequence and the cleaved primary polynucleotide sequence which is identical with the primary polynucleotide sequence, and reforming the complex of the primary polynucleotide sequence with the single stranded pattern polynucleotide which is usually in excess.
- the above steps are repeated until the desired number of copies are obtained.
- the target polynucleotide sequence can be part of a polynucleotide analyte that is to be detected.
- One aspect of the invention comprises a determination of such a polynucleotide analyte by causing the target polynucleotide sequence to initiate the above described method for producing multiple copies.
- the target polynucleotide sequence in the polynucleotide analyte is caused to terminate in a 3′ hydroxyl group when it is not already so terminated. This is usually effected by incubation with a restriction endonuclease.
- the target sequence is dissociated from complementary polynucleotides and caused to hybridize with the single stranded pattern polynucleotide which has a complementary binding polynucleotide sequence bound at the 3′ end of the template sequence.
- the formation of multiple copies of the primary polynucleotide sequence is then carried out by an extension of the target sequence along the single stranded pattern polynucleotide and cleavage of the extension into fragments as described above for the hybrid of the primary polynucleotide sequence with the single stranded pattern polynucleotide.
- the cleaved fragments are detected, and their presence indicates the presence of the polynucleotide analyte in the sample.
- the hybridization, chain extension, and cleaving can be repeated until the single stranded polynucleotide or nucleoside triphosphates are exhausted or the template-dependent polynucleotide polymerase becomes inactive, but will preferably not be repeated after the ratio of the cleaved fragments induced by the target polynucleotide sequence to those non-specifically induced ceases to increase.
- the present method has application to the detection of both DNA and RNA sequences.
- composition of the present invention is a single stranded pattern polynucleotide that comprises an oligomer consisting of three to one-hundred monomeric units.
- Each monomeric unit consists of an identical oligodeoxynucleotide template having from about eight to one hundred, preferably 10 to 100, bases and at least one restriction site.
- the oligomer is substituted at the 3′ end by a binding polynucleotide sequence of 15 or more bases that is complementary to a target polynucleotide sequence.
- the single stranded pattern polynucleotide is substituted at the 3′ end with a chemical functionality that prevents chain extension with a template dependent polynucleotide polymerase, or is cyclic.
- Polynucleotide analyte--a compound or composition to be measured which is a polymeric nucleotide having about 20 to 500,000 or more nucleotides, usually about 100 to 200,000 nucleotides, more frequently 500 to 15,000 nucleotides.
- the polynucleotide analytes include nucleic acids from any source in purified or unpurified form including DNA (dsDNA and ssDNA) and RNA, including t-RNA, m-RNA, r-RNA, mitochondrial DNA and RNA, chloroplast DNA and RNA, DNA-RNA hybrids, or mixtures thereof, genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and fragments thereof, and the like.
- the polynucleotide analyte can be only a minor fraction of a complex mixture such as a biological sample.
- the analyte can be obtained from various biological material by procedures well known in the art. Some examples of such biological material by way of illustration and not limitation are disclosed in Table I below.
- the polynucleotide analyte where appropriate, will be treated to cleave the analyte to obtain a fragment that contains a target polynucleotide sequence located at the 3′ end of a polynucleotide.
- the analyte can be cleaved by known techniques such as treatment with a restriction endonuclease or other site specific chemical cleavage methods. Such treatment must produce a terminal 3′-hydroxy group or a group convertible to a 3′-hydroxyl group.
- the cleaved fragment obtained from the polynucleotide analyte will usually be at least partially denatured or single stranded or treated to render it denatured or single stranded.
- treatments are well known in the art and include, for instance, heat or alkali treatment.
- double stranded DNA can be heated at 90-100° C. for a period of about 1 to 10 minutes to produce denatured material.
- Target polynucleotide sequence at least a portion of a sequence of nucleotides to be identified, the identity of which is known to an extent sufficient to allow preparation of a binding polynucleotide sequence that is complementary to and will hybridize with such target sequence.
- the target polynucleotide sequence usually will contain from about 12 to 1000 or more nucleotides, preferably 15 to 50 nucleotides.
- the target polynucleotide sequence terminates or can be caused to terminate in a 3′-hydroxyl group and is frequently a part of the polynucleotide analyte.
- the target polynucleotide sequence will generally be a fraction of a larger molecule or it may be substantially the entire molecule.
- the minimum number of nucleotides in the target polynucleotide sequence will be selected to assure that the presence of polynucleotide analyte in a sample will provide at least double the number of copies of target polynucleotide sequence that would be expected to occur by chance in a sample that does not contain the polynucleotide analyte.
- the number of copies expected to occur by chance will be LG/4 n although the frequency of occurrence of a specific sequence in a sample may be greater or less than expected by chance.
- n is the number of nucleotides in the target polynucleotide sequence
- L is the number of base pairs in the genome of the biologic source of the sample
- G is the number of genomic copies present in the sample.
- the maximum number of nucleotides in the target sequence will normally be governed by the length of the polynucleotide analyte and its tendency to be broken by shearing, by endogenous nucleases or by reagents used to cleave the target sequence.
- the target polynucleotide sequence will normally be part of the polynucleotide analyte.
- the target polynucleotide sequence When not part of the analyte, the target polynucleotide sequence will be provided as part of a polynucleotide at a location other than at the 3′ end of the polynucleotide. The presence of the polynucleotide analyte will then cause the target sequence to be cut causing it to terminate at the 3′ end.
- the polynucleotide analyte can be RNA that can be hybridized with a complementary single stranded primer polynucleotide containing the target polynucleotide sequence that includes a cleavage site.
- the hybridized RNA: primer molecule can be treated with a cleavage agent such as a restriction endonuclease capable of cutting heteroduplexes and then denatured to provide a single stranded target sequence terminating in a 3′-OH group.
- a cleavage agent such as a restriction endonuclease capable of cutting heteroduplexes and then denatured to provide a single stranded target sequence terminating in a 3′-OH group.
- Primary polynucleotide sequence a polynucleotide sequence that can be the same as or different from the target polynucleotide sequence and will usually be different.
- the primary polynucleotide sequence is complementary to the template sequence. It will normally be a sequence of eight to 100 bases, usually DNA, preferably 10-75 bases, more preferably 12-50 bases. Frequently, the primary polynucleotide sequence will contain derivatized nucleotides, and it will preferably consist of only two or three of the four nucleotides A and dA or derivatives thereof, U and dT or derivatives thereof, C and dC and derivatives thereof, and G and dG or derivatives thereof . Multiple copies of the primary polynucleotide sequence will be produced in the present method as a result of the presence of the target polynucleotide sequence.
- Single stranded pattern polynucleotide a natural or synthetic sequence of nucleotides that is capable of hybridizing with the primary polynucleotide sequence.
- the single stranded pattern polynucleotide comprises an oligomer of two or more template sequences, preferably two or more copies, preferably at least three, of a template sequence, preferably identical, each containing one or more cleavable sites such as site specific cleavage sequences.
- the template sequence can contain two or three, preferably three, members selected from the group comprising nucleotides, deoxynucleotides, and derivatives thereof.
- the template sequence can preferably consist of only three of the four nucleotides A and dA or derivatives thereof, U and dT or derivatives thereof, C and dC or derivatives thereof, and G and dG or derivatives thereof.
- the template sequence is complementary to the primary polynucleotide sequence.
- the oligomer can be attached at its 3′ end directly or through intermediate nucleotides to the 5′ end of a binding polynucleotide sequence complementary or substantially complementary to the target polynucleotide sequence. Usually, the attachment of the oligomer to the binding polynucleotide sequence will be through one or more site specific cleavage sequences.
- the intermediate nucleotides will also be selected from those bases.
- the single stranded pattern polynucleotide can also contain nucleotides other than those in the binding polynucleotide sequence and the template sequences as long as such nucleotides do not interfere with the present method. Such other nucleotides would usually be outside the binding polynucleotide sequence and the oligomer.
- the single stranded pattern polynucleotide will usually contain from 36 to 4,000 nucleotides, preferably 80 to 1,000 nucleotides and will preferably contain 3 to 100, more preferably 6 to 50, template polynucleotide sequences.
- the single stranded pattern polynucleotide can be DNA or RNA, preferably DNA, and can be linear or circular, preferably circular. It can be a synthetic oligonucleotide or constructed from a virus, plasmid, or the like. When not cyclic it will usually be terminated at its 3′ end by a group that will interefere with chain extension by nucleic acid polymerases.
- a critical feature of the single stranded pattern polynucleotide sequence is that it be free from any polynucleotide sequence that is either complementary or can form an extension along the single stranded pattern polynucleotide sequence that is complementary to the template or binding polynucleotide sequences. Furthermore, where the single stranded pattern polynucleotide sequence is non-cyclic, it is preferably terminated at the 3′ end with a group incapable of reacting in a chain extension reaction sequence by template-dependent polynucleotide polymerase. In this way random initiation of chain extension along the template is prevented.
- Examples of such a group are dideoxynucleotides, such as dideoxythymidine, dideoxyadenosine, dideoxyguanosine, and dideoxycytidine, isopropylphosphoryl, phosphate, N-(trimethyl ammonium ethyl) carbamoyl, polysaccharides such as dextran, polystyrene, hydrazones, proteins, and deoxyribose-3′-phosphoryl and the like.
- dideoxynucleotides such as dideoxythymidine, dideoxyadenosine, dideoxyguanosine, and dideoxycytidine
- isopropylphosphoryl phosphate
- N-(trimethyl ammonium ethyl) carbamoyl polysaccharides such as dextran, polystyrene, hydrazones, proteins, and deoxyribose-3′-phosphoryl and the like.
- Dideoxynucleotide capping can be carried out according to conventional techniques such as, described by Atkinson, et al . (1969) Biochem ., 8 : 4897-4904. Hydrazone formation can be obtained by oxidation of a ribonucleotide at the 3′ end with periodate to form a dialdehyde, which can then react with substituted hydrazines such as dinitrophenylhydrazine, positively charged hydrazines such as 2-trimethylammonium-1-ethylhydrazine, hydrazines bonded to dextran and proteins, particularly hydrazide derivatives of carboxyalkyldetrans and proteins, etc., and the like.
- Such 3′ blocked material may then be separated from other reaction mixture components by affinity chomatography and other techniques well known in the art.
- Aldehyde formation followed by derivatization of the aldehyde is one general procedure for blocking the 3′ end of the template. See, for example, Reines, et al . (1974) Nucleic Acids Research , 1 :767-786.
- a 3′-terminal phosphate group can be achieved, for example, by treating the single stranded polynucleotide terminated with a ribonucleotide with periodate and ⁇ -elimination by cyclohexylamine or benzylamine (See Krynetskaya et al .
- Terminal 3′ blocking may also be achieved by covalent attachment of the 3′ end to a glass bead, resin, or any other suitably modified particle or bead. This means of blocking the 3′ functionality is commonly practiced under a number of forms in the synthesis of oligonucleotides.
- a specific embodiment of a single stranded pattern polynucleotide that can be utilized in the present invention is one in which the oligomer consists of only three nucleotide members selected from the group consisting of dA, dC, dG and dT or derivatives of these nucleotide members that have similar complementarity of binding to nucleotide bases as the parent member and do not interfere with template dependent polynucleotide polymerases, when incorporated in the template polynucleotide sequence.
- the single stranded pattern polynucleotide can be obtained by cloning or synthesis. Synthetic procedures and isolation methods can be automated or not. Such methods include phosphotriester and phosphodiester methods (Narang, et al . (1979) Meth. Enzymol 68 :90) and synthesis on a support (Beaucage, et al . (1981) Tetrahedron letters 22 :1859-1862) as well as the phosphoramidite technique and others described in "Synthesis and Applications of DNA and RNA," S.A. Narang, editor, Academic Press, New York, 1987, and the references contained therein.
- the single stranded pattern polynucleotide often comprises 5 to 50 template sequences connected by one or more site specific cleavage sequences.
- Template sequence a sequence of nucleotides, at least one of which is complementary to the primary polynucleotide sequence, located within the single stranded pattern polynucleotide and present usually as a tandem repeat including one or more cleavable sites such as site specific cleavage sequences.
- the number of nucleotides in the template sequence should be sufficiently high that stringency conditions used to hybridize with the primary polynucleotide sequence will prevent excessive random non-specific hybridization and not so high that the conditions needed to dissociate the template sequence from the primary polynucleotide sequence will inactivate the template dependent polynucleotide polymerase.
- the number of nucleotides in the template sequence is from 8 to 100, preferably, 10 to 75, more preferably, 12 to 30. 10 to 20 is also a very useful number. Usually, from about three to 100 copies of the template sequence are present in the single stranded pattern polynucleotide.
- Site specific cleavage sequence a sequence of nucleotides in a polynucleotide that, when complexed with a complementary polynucleotide having a cleavable polynucleotide sequence, will promote cleavage of such complementary cleavable polynucleotide sequence at a specific site within the sequence. An additional reagent will usually be required for cleavage.
- the site specific cleavage sequence will usually consist of 4 to 30 nucleotides, more usually 4 to 15 nucleotides, preferably 4 to 8 nucleotides.
- the complex of the site specific cleavage sequence and the polynucleotide having the cleavable polynucleotide sequence will comprise a restriction endonuclease site and the additional reagent will be a restriction endonuclease.
- Type I restriction endonucleases recognize a specific nucleotide sequence and make a cut nearby, without any specificity as to the nucleotide sequence that is cut. Consequently, utilization of a cleavage promoting sequence recognized by a Type I restriction endonuclease would require the use of a second reagent or the presence of a derivatized nucleotide in the site specific cleavage sequence that would provide for cleavage at a specific site.
- Type II restriction endonucleases recognize a specific sequence and make a double strand cut at a fixed point within that sequence. Such sequences usually have a central axis of symmetry and read identically in both directions from that axis.
- Type II restriction endonucleases are of most general utility in the method of the invention.
- Type III restriction enzymes recognize asymmetric restriction sites that are a specific sequence and make a double strand cut at a fixed point some number of nucleotides to the side of such sequence. Type III enzymes are therefore also of use in this method.
- nucleotide sequences and the restriction endonucleases that recognize them are set out in Table II below and in Kassler and Höltke (1986) Gene 47 :1-153 and Roberts (1987) Nucleic Acids Res. 15 :r189 - r217, and references contained therein.
- the site specific cleavage sequence will frequently be cut but is not required to be cut during the method of the present invention as long as the reagent required for cleavage is capable of cleaving a cleavable polynucleotide sequence in a polynucleotide that is complementary and bound to the specific cleavage sequence.
- a site specific cleavage sequence is a methylated sequence corresponding to one of those given above in Table II.
- Methylation of the site specific cleavage sequences of the single stranded pattern polynucleotide can be achieved by introducing a methylated nucleotide in the synthesis of the single stranded pattern polynucleotide or by using an enzyme such as methyl transferase, or the like.
- a cleaving agent that recognizes and cleaves hemi-methylated sites is employed.
- an enzyme such as Taq I which can cut the unmethylated strand of TCG96mA/TCGA duplexes or Sau 3AI, MspI, AccI or Xho II or the like can be employed.
- a cleavable sequence formed during the method of the invention is a DNA sequence produced utilizing an RNA template sequence or a RNA sequence produced utilizing a DNA template sequence wherein the cleaving agent cleaves only RNA or DNA, a DNA/RNA hybrid, as the case may be. Cleavage of DNA and possibly RNA also in a DNA:RNA hybrid has been described by Molloy and Symms (1980) Nucleic Acids Res. 8 , 2939-2946.
- Nucleoside triphosphates a nucleoside having a 5′ triphosphate substituent, usually a deoxynucleoside triphosphate.
- the nucleosides are pentose sugar derivatives of nitrogenous bases of either purine or pyrimidine derivation, covalently bonded to the 1′-carbon of the pentose sugar.
- the purine bases include adenine(A), guanine(G), and derivatives and analogs thereof.
- the pyrimidine bases include cytosine (C), thymine (T), uracil (U), and derivatives and analogs thereof.
- the deoxynucleotide triphosphates are dATP, dGTP, dCTP and dTTP, more often three members of this group or derivatives thereof.
- the derivatives and analogs are exemplified by those that are recognized and polymerized in a similar manner to the underivatized nucleotide triphosphates.
- Examples of such derivatives or analogs by way of illustration and not limitation are those which are modified with a reporter group, biotinylated, amine modified, radiolabeled, alkylated, and the like and also include thiophosphate, phosphite, ring atom modified derivatives, and the like.
- the reporter group can be a fluorescent group such as fluoroscein, a chemiluminescent group such as luminol, a terbium chelator such as N-(hydroxyethyl) ethylenediaminetriacetic acid that is capable of detection by delayed fluorescence, and the like.
- the reporter group is selected from the group consisting of biotin, fluorescers, chemiluminescers, and small organic molecules.
- Template-dependent polynucleotide polymerase (TDPP)-- a catalyst, usually an enzyme, for forming an extension of the primary polynucleotide sequence or the target polynucleotide sequence, as the case may be, along the single stranded pattern polynucleotide where the extension is complementary to the template sequence.
- the template-dependent polynucleotide polymerase utilizes the nucleoside triphosphates as the building blocks for the extension which proceeds in a 5′ to 3′ (3′ to 5′ with respect to the template) direction until extension terminates.
- the catalysts are enzymes, such as RNA polymerases, preferably DNA polymerases such as, for example, prokaryotic DNA polymerase (I, II, or III), T4 DNA polymerase, T7 DNA polymerase, Klenow fragment, reverse transcriptase, RNA replicases, and the like derived from any source such as cells, bacteria, such as E . coli , plants, animals, virus, thermophilic bacteria, and so forth.
- DNA polymerases such as, for example, prokaryotic DNA polymerase (I, II, or III), T4 DNA polymerase, T7 DNA polymerase, Klenow fragment, reverse transcriptase, RNA replicases, and the like derived from any source such as cells, bacteria, such as E . coli , plants, animals, virus, thermophilic bacteria, and so forth.
- Means for specifically cleaving a cleavable site such as a polynucleotide sequence when the cleavable polynucleotide sequence is hybridized with a complementary polynucleotide having a site specific cleavage sequence -- usually a catalyst.
- a cleavable polynucleotide sequence is a restriction endonuclease recognition site
- such means is usually a restriction endonuclease, which is an enzyme capable of cutting double strand DNA at or near a particular nucleotide sequence.
- Such means can also be a chemical compound that specifically reacts with a base resulting in cleavage. See, for example, Peter Dervan (1986) Science 232 :464-471.
- Cleavage of a specific sequence may also be achieved by incorporating in the site specific cleavage sequences a cleavage promoting group such as a chelate iron atom or a photoactivator.
- each subcombination can then be subjected to one or more steps of the present method.
- each of the subcombinations can be incubated under conditions to achieve one or more of the desired results.
- One embodiment of the method of the present invention is directed to the production of multiple copies of a primary polynucleotide sequence as the result of the presence of a target polynucleotide sequence substantially identical to the primary polynucleotide sequence located at the 3′ terminus of a polynucleotide.
- a combination is prepared either wholly or partially sequentially or simultaneously comprising the target polynucleotide sequence, single stranded pattern polynucleotide, nucleotide triphosphates, template-dependent polynucleotide polymerase, and means for specifically cleaving cleavable polynucleotide sequences.
- the combination is incubated under conditions for either wholly or partially sequentially or simultaneously hybridizing the target sequence with single stranded pattern polynucleotide, forming a chain extension of the target sequence comprising one or more copies of a polynucleotide sequence complementary to the template sequence connected through cleavable polynucleotide sequences, cleaving the extension into fragments at the cleavable polynucleotide sequences, denaturing the fragments, hybridizing the fragments with single stranded pattern polynucleotide, and forming a chain extension of the hybridized fragment.
- the above steps are repeated until the desired number of copies is obtained.
- FIG. 1 One method for obtaining multiple copies of a primary polynucleotide sequence is represented in FIG. 1.
- the single stranded pattern polynucleotide (1) comprised of repeating template sequences (1a) containing restriction endonuclease sites ( ⁇ ) is incubated with the primary polynucleotide sequence (2) under temperature and solvent conditions suitable for at least partial hybridization of (1) and (2) to form a duplex (3) in which the 3′-OH of (2) corresponds to the cleavage point in the restriction endonuclease site.
- duplex (3) reacts with nucleotide triphosphates (NT) by catalysis with template dependent polynucleotide polymerase (TDPP) to extend the primary polynucleotide sequence (2) to form the extended duplex (4).
- NT nucleotide triphosphates
- TDPP template dependent polynucleotide polymerase
- duplex (4) reacts with a restriction endonuclease (RE) to form duplex fragments (5) consisting of the template sequence (1a) and the primary polynucleotide sequence (2).
- Duplex fragments (5) dissociate to give multiple copies of the single stranded primary polynucleotide sequence (2) which reenter the cycle.
- the single stranded pattern polynucleotide (1) can also include nucleotide sequences bound to its 3′ and 5′ ends, and these sequences may be connected to form a ring.
- the repeating template sequences will be made up of only two or three, preferably three, of the four natural nucleotides, dA or A, dT or U, or dG or G, and dC or C, or derivatives thereof. Under this circumstance only the two or three corresponding complementary nucleotide triphosphates or derivatives thereof are included in the polymerization reaction.
- a method for analyzing for a polynucleotide analyte involves causing the analyte to effect formation of primary polynucleotide sequence from which multiples can be formed by the method of this invention and detecting these copies.
- One method (B) for effecting forming of a primary polynucleotide sequence by the polynucleotide analyte is depicted in FIG. 2.
- a polynucleotide analyte (6) containing a target polynucleotide sequence (6a) is denatured and then hybridized with excess single stranded pattern polynucleotide (1) having a portion of its template sequence (1a) complementary to the target polynucleotide sequence (6a).
- the resulting hybrid (7) is then treated with a restriction enzyme (RE) to form a free hydroxy at the 3′ end of the target polynucleotide sequence (6b).
- RE restriction enzyme
- This target polynucleotide sequence which forms as a duplex (8) with at least a portion of the single stranded pattern polynucleotide (1), is dissociated from the duplex (8) and is hybridized to another molecule of single stranded pattern polynucleotide (1) to form the new duplex (9).
- the duplex (9) reacts with nucleoside triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend target polynucleotide sequence (6b) and form an extended duplex (10).
- duplex (10) reacts with a restriction endonuclease (RE) to form duplex fragments (5) which can dissociate into primary polynucleotide sequence (2) as illustrated in method (A).
- NT nucleoside triphosphates
- TDPP template-dependent polynucleotide polymerase
- RE restriction endonuclease
- FIG. 3 Another method for effecting formation of a primary polynucleotide sequence by the presence of a polynucleotide analyte is depicted in FIG. 3.
- the polynucleotide analyte (6) is first treated with a restriction enzyme (RE) that cuts the target polynucleotide sequence (6a) to produce duplex (11) containing the target polynucleotide sequence (6b) terminating in a 3′-hydroxy group. This duplex is then dissociated, and the cleaved target polynucleotide sequence is hybridized with excess single stranded pattern polynucleotide (1) to form duplex (9).
- Duplex (9) is extended according to method (B) for forming a primary polynucleotide sequence.
- duplex (11) is dissociated and rehybridized with a single standed pattern polynucleotide (12) which contains at least one template sequence (1a) and a binding polynucleotide sequence (12a) at its 3′ end that is complementary to target sequence (6b).
- (12) is cyclic and in no case can it be susceptible to chain extension by template dependent polynucleotide polymerase in the absence of a cleavage agent.
- duplex (13) reacts with nucleotide triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend the target polynucleotide sequence (6b) to form the extended duplex (14).
- Duplex (14) reacts with a restriction enzyme (RE) to form duplex fragments (5) which can dissociate into primary polynucleotide sequence (2) as illustrated in method (A).
- RE restriction enzyme
- E (FIG. 5) for eliciting formation of a primary polynucleotide sequence by presence of a polynucleotide analyte, preferably an RNA analyte, (6′) having a sequence of polynucleotides to be identified (6a′), the analyte is dissociated into single strands, if it is not already single stranded. It is then hybridized with a primer polynucleotide (15) comprised of a primary polynucleotide sequence (2) with its 3′ end bound to a binding polynucleotide sequence (15a).
- a primer polynucleotide comprised of a primary polynucleotide sequence (2) with its 3′ end bound to a binding polynucleotide sequence (15a).
- hybrid (16) After formation of hybrid (16), the hybrid is cut by a restriction enzyme to give the primary polynucleotide sequence (2) with a free 3′-OH suitable for formation of multiple copies according to method (A).
- FIG. 6 Another method (F) (FIG. 6) for effecting formation of a primary polynucleotide sequence as a result of the presence of a polynucleotide analyte requires a single stranded pattern polynucleotide (18) comprised of a binding polynucleotide sequence (18a) connected at its 5′ end to an oligomer of template sequences (1a).
- a duplex (11) containing a target polynucleotide sequence (6b) ending in a 3′-hydroxyl is produced in response to the presence of a polynucleotide analyte according to Methods (B) or (C).
- duplex is denatured and the sequence (6B) is hybridized with the single stranded pattern polynucleotide (18).
- the resulting hybrid (19) reacts with nucleotide triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend the target polynucleotide sequence (6b) and form an extended duplex (20).
- Duplex (20) reacts with a restriction endonuclease (RE) to form duplex fragments (5) which can dissociate into the primary polynucleotide sequence (2) as illustrated in Method (A).
- duplex (21) is found which can dissociate and hybridize with single stranded pattern polynucleotide (18) to reform hybrid (19).
- an aqueous medium will be employed.
- Other polar cosolvents may also be employed, usually oxygenated organic solvents of from 1-6, more usually from 1-4, carbon atoms, including alcohols, ethers and the like. Usually these cosolvents will be present in less than about 70 weight percent, more usually in less than about 30 weight percent.
- the pH for the medium will usually be in the range of about 4.5 to 9.5, more usually in the range of about 5.5 - 8.5, and preferably in the range of about 6 - 8.
- the pH and temperature are chosen and varied, as the case may be, so as to provide for either simultaneous or sequential hybridization of the target sequence with the single stranded pattern polynucleotide, extension of the target sequence, cleavage of the extension into fragments at the cleavable polynucleotide sequences, reversible denaturation of the fragments, hybridization the fragments with single stranded pattern polynucleotide, and extension of the hybridized fragments. In some instances, a compromise will be made between these considerations depending on whether the above steps are performed sequentially or simultaneously.
- buffers may be used to achieve the desired pH and maintain the pH during the determination.
- Illustrative buffers include borate, phosphate, carbonate, Tris, barbital and the like.
- the particular buffer employed is not critical to this invention but in individual methods one buffer may be preferred over another.
- Moderate temperatures are normally employed for carrying out the method and desirably constant temperatures during the period for conducting the method.
- a constant temperature will usually be selected near the melting temperature of the complex of primary polynucleotide sequence and the template sequence.
- the option to utilize a constant temperature is a benefit realized in the present method that arises because the length of the primary polynucleotide sequence and the newly formed copies thereof are identical.
- the temperatures for the method will generally range from about 20 to 90°C, more usually from about 30 to 70°C preferably 37 to 50°C. However, the temperature can be varied depending on whether the above steps are carried out sequentially or simultaneously. For example, relatively low temperatures of from about 20 to 40°C can be employed for the chain extension and cleavage steps, while denaturation and hybridization can be carried out at a temperature of from about 40 to 80°C.
- the time period for carrying out the method of the invention will generally be long enough to achieve a desired number of copies of the primary polynucleotide sequence. This, in turn, depends on the purpose for which the amplification is conducted, such as, for example, as assay for a polynucleotide analyte. Generally, the time period for conducting the method will be from about 5 to 200 min. As a matter of convenience it will usually be desirable to minimize the time period. In general, the time period for a given degree of amplification can be shortened, for example, by selecting concentrations of nucleoside triphosphates, sufficient to saturate the template dependent nucleotide polymerase and by increasing the concentrations of template-dependent polynucleotide polymerase.
- a particularly critical factor is the efficiency of the means to cleave site specific cleavage sequences. It will generally be desirable to select conditions that maximize the cleavage rates, for example, by use of a restriction enzyme having a high turn over and optimizing its concentration. Another critical factor in reducing the time period is the number of template sequences present in the single stranded pattern polynucleotide.
- the number of copies of polynucleotide sequence that are formed will increase exponentially with each extension.
- at least three template sequences are present whereupon the number of copies doubles with each extension of the primary polynucleotide sequence.
- More preferably at least five template sequences are present and the number of copies triples with each extension.
- the number of copies present after each extension should multiply by about (n+1)/2 where n is the number of template sequences in the single stranded pattern polynucleotide.
- the concentration of the target polynucleotide sequence which is to be copied can be as low as one or two molecules in a sample but will generally vary from about 102 to 1010, more usually from about 103 to 108.
- the concentration of the single stranded pattern polynucleotide sequence will usually depend on the number of copies desired, and the rate at which such copies are formed will normally determine the concentration of the other reagents and the number of template sequences in the single stranded pattern polynucleotides.
- the final concentration of each of the reagents will normally be determined empirically to optimize the number of the copies of the target sequence.
- the concentration of the single stranded pattern polynucleotide and the deoxynucleoside triphosphates in the medium can vary widely; preferably, these reagents are present in an excess amount.
- the deoxynucleoside triphosphates will usually be present in 10 ⁇ 6 to 10 ⁇ 2M, preferably 10 ⁇ 5 to 10 ⁇ 3M.
- the single stranded pattern polynucleotide will usually be present in at least 10 ⁇ 12M, preferably 10 ⁇ 10M, more preferably at least about 10 ⁇ 8M.
- the concentration of the template-dependent polynucleotide polymerase and the means for cleaving the cleavable site such as the site specific cleavable sequence, which is usually a restriction endonuclease and any cofactors thereof in the medium can also vary substantially.
- These reagents may be present in as low as 10 ⁇ 12M but may be present in a concentration at least as high or higher than the concentration of the single stranded pattern polynucleotide.
- the primary limiting factor being the cost of the reagents, which are usually enzymes.
- the order of combining of the various reagents to form the combination may vary. Generally, a target polynucleotide sequence located at the 3′ terminus of a polynucleotide is obtained. This may be combined with a pre-prepared combination of single stranded pattern polynucleotide sequence, nucleoside triphosphates, template-dependent polynucleotide polymerase, and cleaving agent. However, simultaneous addition of the above, as well as other step-wise or sequential orders of addition, may be employed.
- concentration and order of addition of reagents and conditions for the method are governed generally by the desire to maximize the number of copies of the primary polynucleotide sequence and the rate at which such copies are formed.
- One aspect of the present invention concerns the determination or detection of a polynucleotide analyte terminating in, or caused to be terminated in, a 3′-hydroxy nucleotide.
- the polynucleotide analyte will generally be present in a sample suspected of containing the polynucleotide analyte.
- the method comprises providing in combination in an aqueous medium either sequentially or simultaneously one or more of the polynucleotide analyte, an exogeneously added single stranded pattern polynucleotide capable of hybridizing with the polynucleotide analyte, nucleoside triphosphates, and template-dependent polynucleotide polymerase.
- the medium is incubated under conditions for either sequentially or simultaneously hybridizing at least a target sequence in the polynucleotide analyte with single stranded pattern polynucleotide, forming an extension of the target sequence along the template, cleaving the extension into fragments, denaturing the fragments by hybridizing the fragments with single stranded pattern polynucleotide, and forming an extension of the fragments.
- the above steps are repeated under the reaction conditions until a detectible number of fragments are obtained. Thereafter, the fragments, or fragments complementary thereto, are detected and the presence of the fragments indicates the presence of the polynucleotide analyte in the sample.
- the sample Prior to providing the combination, the sample can be incubated sequentially (1) with reagents for modifying the 3′ end of any polynucleotide in the sample to prevent free 3′ ends from reacting with the template-dependent polymerase and (2) with a restriction enzyme capable of producing a hydroxyl group at the 3′ end of the polynucleotide analyte to be determined.
- the reagents for modifying the 3′ end of a polynucleotide can comprise an enzyme capable of catalyzing the reaction of the polynucleotide 3′-hydroxyl group. Examples of such an enzyme are polynucleotide ligases from any source such as E.
- the ligases referred to above additionally can include an oligonucleotide terminated at the 3′ end with a group that does not react to provide chain extension by the template-dependent polynucleotide polymerase.
- the terminal transferase can include a dideoxynucleotide triphosphate, methylated nucleotide triphosphate, and the like.
- the pH, temperature, solvent, and time considerations will be similar to those described above for the amplification method.
- conditions are chosen for either sequentially or simultaneously hybridizing the polynucleotide analyte with the single stranded pattern polynucleotide, forming an extension along the pattern polynucleotide, cleaving the extension into fragments, reversibly denaturing the fragments, hybridizing the fragments with single stranded pattern polynucleotide, and forming an extension of the fragments.
- the concentration of polynucleotide analyte which can be assayed will be similar to those described above for the concentration of the target polynucleotide sequence.
- concentrations of the various reagents will generally be determined by the concentration range of interest of the polynucleotide analyte
- concentration of each of the reagents will normally be determined empirically to optimize the sensitivity of the assay over the range of interest.
- concentration of the other reagents in an assay generally will be determined following the same principles as set forth above for the amplification methods.
- the primary consideration is that a sufficient number of copies of a primary polynucleotide sequence be produced in relation to the polynucleotide analyte sequence so that such copies can be readily detected and provide an accurate determination of the polynucleotide analyte.
- any fragments present are detected.
- the presence of the fragments indicates the presence of the polynucleotide analyte in the sample.
- the fragments can be detected in numerous ways. Essentially any method for detection of nucleic acids can be utilized in detecting the fragments formed in the assay method in the present invention. Alternatively, any method for detection of pyrophosphate formed during the polymerization can be utilized.
- Any standard method for detecting double strand nucleic acid can be used such as, for example, precipitation of the single strand material with trichloracetic acid and measurement of light absorption of the solution, intercalating of a dye, such as ethidium bromide, and the like, followed by spectroscopic measurement, measurement of changes in hyperchromicity, optical rotation measurements, nucleic acid probe hybridization methods, and the like.
- Any of the above detection methods can be utilized in conjunction with a preliminary chromatographic separation step to separate double strand fragments the size of the hybridized or unhybridized primary polynucleotide sequence from higher and lower molecular weight material in the medium.
- the above procedures are well known in the art and will not be described in great detail but rather will be described in a summary fashion in the following paragraphs.
- On method for detecting nucleic acids is to employ nucleic acid probes.
- This method generally involves immobilization of the target nucleic acid on a solid support such as nitrocellulose paper, cellulose paper, diazotized paper, or a nylon membrane. After the target nucleic acid is fixed on the support, the support is contacted with a suitably labelled probe nucleic acid for about two to forty-eight hours. After the above time period, the solid support is washed several times at elevated temperatures to remove unbound probe. The support is then dried and the hybridized material is detected by autoradiography or by colorimetric methods.
- the method comprises combining in an assay medium the sample and first and second polynucleotide reagents complementary to the nucleic acid fragment. Each of the first and second reagents hybridize with a different region of nucleic acid fragment.
- the first reagent contains means for rendering the first reagent non-covalently polymerizable.
- the second reagent contains means for rendering the second reagent detectable.
- the sample and the first and second reagents are combined in the assay medium under conditions for polymerizing the first reagent wherein the second reagent becomes bound to the polymerized first reagent only when the DNA fragment is present in the sample. A determination is then made as to whether the second reagent has become bound to the polymerized first reagent.
- the primary polynucleotide sequence can be labeled with a ligand by having present a ligand substituted nucleotide triphosphate in the combination of reagents.
- the template sequence can be labeled with a second ligand.
- the complex of these two sequences that is formed in the method can be detected by causing the complex to bind to a surface to which is bound a receptor for one of the ligands.
- a receptor for the other ligand that is labeled with a detectable group such as an enzyme or fluorophore can then be caused to bind to the other ligand in proportion to the amount of the complex that binds to the surface.
- Another method for detecting the nucleic acid fragments involves dyes possessing an affinity for DNA or RNA.
- dyes are DNA intercalating agents, which are generally well known compounds and are, for the most part, commercially available.
- DNA intercalating agents are acriflavine, acriflavine hydrochloride, and like acridine derivatives, and ethidium halides such as ethidium bromide.
- the above method can also be applied to the determination of the presence of an RNA analyte in a sample suspected of containing such RNA analyte.
- the RNA polynucleotide analyte is provided by combining in an aqueous medium the sample, a single stranded DNA primer comprising a deoxynucleic acid sequence containing a restriction site and capable of hybridizing with the RNA sequence, and a restriction enzyme capable of cleaving the primer at the restriction site when the primer is hybridized with the RNA sequence.
- the combination is incubated for a time sufficient to permit cleaving to occur under conditions for cleaving the hybridized primer at the restriction site. Such conditions are similar to those described above for cleaving the site specific cleavage sequences.
- the cleaved primer can then serve as the target sequence in the above method.
- the DNA primer can be cyclic or can be terminated at its 3′ end by a group incapable of reacting in a reaction catalyzed by the template-dependent polynucleotide polymerase.
- One embodiment of the present invention is a method of producing multiple polynucleotide molecules as a function of the presence of a target sequence of nucleotides in a polynucleotide sample.
- the method comprises combining the polynucleotide sample either simultaneously or wholly or partially sequentially with one or more of (1) means to cause the target sequence to terminate in a 3′ hydroxy group when the target sequence does not already terminate in such group, (2) single stranded pattern polynucleotide comprising a binding polynucleotide sequence complementary to substantially all of the target sequence and a site specific cleavage sequence joined at the 5′ end of the binding polynucleotide sequence wherein the 5′ end of the site specific cleavage sequence is joined to the 3′ end of the template sequence (4) nucleoside triphosphates, (5) template-dependent polynucleotide polymerase, and (6) means for cleaving the sequence complementary to the site specific cleavage sequences when hybridized with the site specific
- the combining is carried out under conditions which promote wholly or partially, either sequential or simultaneous denaturation of the target sequence when the target sequence is double stranded, hybridization of the target sequence with the template, extension of the target sequence by template-dependent polynucleotide polymerase to produce a duplex, cleavage of the extension in the duplex into fragments, denaturation of the duplex, hybridization of the fragments with single stranded pattern polynucleotide, and extension of the said fragments.
- the above steps are repeated until the desired number of copies is obtained.
- Another embodiment of the present invention is a method for determining the presence of a polynucleotide analyte in a sample suspected of containing said polynucleotide analyte.
- the method comprises combining in an aqueous medium either wholly or partially sequentially or simultaneously (1) said sample, (2) means for obtaining from the polynucleotide analyte a target sequence and for terminating the sequence in a 3′-OH group, (3) single stranded pattern polynucleotide comprised of a sequence complementary to the target sequence joined at its 5′ end to a multiply repeated sequence of at least 12 nucleotides, said repeated sequence, when hybridized to its complementary sequence and incubated with a restriction enzyme, promoting cleavage of the complementary sequence to form restriction fragments, (4) deoxynucleoside triphosphates, (5) a DNA dependent nucleotide polymerase for extending the target sequence to provide said complementary sequence, and (6) a restriction endonucleases for
- the combining is carried out under conditions for either wholly or partially sequentially or simultaneously obtaining the target sequence from the polynucleotide analyte, hybridizing the target sequence to the single stranded pattern oligonucleotide, extending the target sequence to form the complementary sequence, cleaving the complementary sequence into fragments, denaturing the hybridized duplex of the complementary sequence and the repeated sequence, hybridizing the fragments with single stranded pattern polynucleotide, and extending the fragments to form complementary sequences.
- the method further includes detecting cleaved complementary sequence. The presence of the cleaved complementary sequence indicates the presence of the polynucleotide analyte in said sample.
- Another embodiment of the present method is directed to determining the presence of a target sequence of nucleotides in a polynucleotide analyte in a sample suspected of containing the polynucleotide analyte.
- the method comprises combining said sample either wholly or partially sequentially or simultaneously with one or more of (1) means capable of causing the target sequence to be terminated in a 3′-OH group, (2) a single stranded pattern oligodeoxynucleotide template comprised of a sequence complementary to the target sequence, the sequence bonded at its 5′ end to a multiply repeating sequence of at least 12 nucleotides which, when hybridized to a complementary sequence allows cleavage of said complementary sequence to form fragments, (3) deoxynucleoside triphosphates, (4) DNA dependent DNA polymerase and (5) a restriction enzyme for cleaving the complementary sequence when hybridized to the cleavage promoting sequence.
- the method further comprises incubating the individual components and mixtures formed therefrom under conditions which promote either wholly or partially sequential or simultaneous (a) denaturation of the target sequence when the target sequence is double stranded, (b) hybridization of the target sequence with the template, (c) extension of the target sequence by DNA dependent DNA polymerase to produce a duplex containing the complementary sequence, (d) cleavage of the complementary sequence in the duplex into fragments, (e) melting of the duplex, and f(f) hybridization of the fragments with single stranded pattern polynucleotide, and extension of the fragments by DNA dependent DNA polymerase to produce a duplex containing the complementary sequence and repeating the above steps. Thereafter, the complementary sequence or fragments of the template produced during cleavage of said complementary sequence are detected. The presence thereof indicates the presence of the analyte in said sample.
- Another aspect of the present invention involves a polydeoxynucleotide comprising a single stranded DNA oligomer consisting of from about 3 to 100, preferably 6 to 50, oligonucleotide units and at least one restriction site.
- Each oligodeoxynucleotide unit consists of an oligodeoxynucleotide template containing at least one restriction site and having from about 8 to 100, preferably 10 to 50 nucleotides.
- the monomer units are identical.
- the oligodeoxynucleotide can be cyclic or non-cyclic and is preferably cyclic.
- the DNA oligomer can be bonded at its 3′ end to a single stranded polynucleotide binding sequence consisting of at least about 15 nucleotides.
- the oligomer and any polynucleotide sequence connecting the oligomer and the binding sequence are composed of two or three, preferably three, members selected from the group of nucleotides and deoxynucleotides or a corresponding derivative thereof.
- the nucleotides are selected from three members of the group consiting of A and dA or a derivative thereof, U and dT or a derivative thereof, G and dG or a derivative thereof and C and dC or a derivative thereof.
- the 5′ end of the DNA oligomer can be connected directly or through a polynucleotide sequence to the 3′ end of the binding sequence to form a ring.
- the oligonucleotide can preferably contain from about 3 to 100, preferably 6 to 50, template sequences, and the template sequences can preferably each consist of from about 8 to 100, preferably 10 to 50, more preferably 10 to 20, nucleotides.
- Reporter groups can be bound to the DNA oligomer, preferably, one reporter group per monomer unit.
- the reporter groups include radioactive molecules, fluorescers, chemiluminescers, small organic groups of molecular weight of from about 17 to 1000 such as biotin, NH2, OH, SH, fluorescein, etc., and the like.
- the single stranded pattern polynucleotide can be prepared by enzymatic ligation.
- An appropriate oligonucleotide which is identical to the template or upon ligation with itself forms a template sequence, can be synthesized by standard automated techniques. It is then enzymatically ligated together, for example, by T4 ligase, to produce the single stranded pattern polynucleotide.
- Oligomers of the desired lenght can then be isolated, for example, by polyacrylamide gel electrophoresis or high performance liquid chromatography (HPLC). Frequently, the 3′ end of the oligomer will be modified to prevent reaction with template dependent DNA polymerase or to append a binding sequence, preferably catalyzed by a ligase.
- the 3′-end can also be modified by ligation of a dideoxynucleotide or a ribonucleotide followed by oxidation of the ribose with periodate followed by reductive amination of the resulting dialdehyde with borohydride and a bulky amine such as aminodextran.
- the single stranded polynucleotide can be prepared by recombinant DNA technology.
- the single stranded pattern polynucleotide can be synthesized entirely by standard solid phase automatable methods as, for example, by use of phosphoamidates. In this method the group anchoring the synthetic sequence to the solid support can be released at the last step and can serve to prevent reaction of the 3′ end with DNA polymerase.
- the single stranded pattern polynucleotide may be left covalently bonded at the 3′ end to a solid support and thus blocked.
- the solid support can be, for example, a bead, sheet, particle, or the like composed of synthetic or natural material such as, for example, organic polymer, glass, inorganic polymer and the like. This material may be subsequently extented at its 5′ end and increased in the number of its template units by chemical or enzymatic ligation with other oligonucleotides.
- the single stranded pattern polynucleotide can be prepared by standard cloning techniques, for example, by use of the cyclic single stranded M13 phage. In this approach the synthetic oligomer terminating in cleaved restriction sites is inserted at the corresponding restriction site into the polylinker region of M13. Where desired, a binding polynucleotide sequence can be similarly inserted. The phage is then cloned and harvested.
- the single stranded pattern polynucleotide be free from complementary polynucleotide sequences. The presence of complementary sequences will result in random initiation of chain extension.
- a particularly preferred composition for use in the method of the present invention is a cyclic single stranded pattern polydeoxynucleotide having at least three contiguous, preferably, identical, template sequences of polydeoxynucleotides. Each template sequence contains at least one restriction site.
- These sequences and any sequence connecting the binding polynucleotide sequence with the template sequence oligomer lack one member of the group of nucleotides comprising adenine (A) and deoxyadenine (dA), guanidine (G) and deoxyguanidine (dG), cytidine (C) and deoxycytidine (dC), and thymidine(T) and deoxythymidine (dT) or a corresponding derivative thereof.
- the template sequence in the above cyclic pattern polynucleotide preferably contains from eight to one hundred nucleotides.
- the cyclic pattern polynucleotide usually contains from about 3 to 50, preferably at least 6 template sequences.
- a preferred cyclic pattern polynucleotide for use in the present method is a synthetic sequence cloned into M13, ⁇ X174, or the like.
- the reagents employed in the present invention can be provided in a kit in packaged combination with predetermined amount s of reagents for use in obtaining multiple copies of a primary polynucleotide sequence or for use in assaying for a polynucleotide analyte in a sample.
- a kit useful in the present method can comprise in packaged combination with other reagents a composition such as that described above.
- the kit can further include in the packaged combination nucleoside triphosphates such as deoxynucleoside triphosphates, e.g., deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP).
- nucleoside triphosphates such as deoxynucleoside triphosphates, e.g., deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP).
- the kit can further include template-dependent polynucleotide polymerase and also means for cleaving the site specific cleavage sequences or the sequences complementary thereto or both. Where the target polynucleotide sequence is RNA, the kit can further include in packaged combination a single
- the DNA primer comprises a nucleic acid sequence capable of hybridizing with the RNA and containing a restriction site.
- the primer is terminated at its 3′ end by a group incapable of reacting in a chain extension in the presence of template-dependent polynucleotide polymerase.
- a restriction enzyme is used for cleaving the cleavable sequences that is different from the restriction enzyme used for providing that the target sequence terminate in a 3′ hydroxyl group
- the kit can further include a packaged combination the restriction enzyme for causing the target sequence or complementary sequence to terminate in a 3′ hydroxy group.
- the kit can include one or more of the above in packaged combination with other reagents for conducting an assay and reagents for detecting DNA fragments as described above.
- kits can be varied widely to provide for concentrations of the reagents which substantially optimize the production of, and the rate of production of, multiple copies of the primary polynucleotide sequence.
- the reagents can be provided to further substantially optimize the sensitivity of the assay.
- one or more of the reagents in the kit can be provided as a dry powder, usually lyophilized, including excipients, which on dissolution will provide for a reagent solution having the appropriate concentrations for performing a method or assay in accordance with the present invention.
- This cycling was accomplished by boiling the reaction mixture, allowing DNA strand renaturation in the presence of excess pattern polynucleotide template at a lower temperature, and continuing the polymerization/cutting by the addition of fresh enzymes. Primary polynucleotide fragments were observed after gel electrophoresis under denaturing conditions. No fragments were observed in control reactions where target DNA was absent.
- M13mp19 single stranded DNA (Lot No. 63102) and the 17 base DNA (Lot No. 62101) were purchased from Bethesda Research Labs (BRL), Gaithersburg, MD.
- the 17 base DNA has the nucleotide sequence 5′ GTAAAACGACGGCCAGT 3′. This DNA functioned as a target polynucleotide sequence in the system described here and is referred to herein also as the target polynucleotide.
- Klenow fragment DNA-dependent DNA polymerase (Lot No. NM 92818; supplied as an FPLCpureTM 7.2 units/ ⁇ l solution) was purchased from Pharmicia Inc., Piscataway, NJ.
- the restriction endonucleases Eco RI (Lot No. 411L1, 10 units/ ⁇ l), Hin d III (Lot No. 51111, 10 units/ ⁇ l), and Bam HI (Lot No. 461D1, 10 units/ ⁇ l) were purchased from BRL.
- the four deoxynucleoside triphosphates (dATP, dGTP, dCTP, and dTTP) were purchased as 100 mM solutions from Pharmacia Inc. Water was sterile filtered Milli-Q reagent grade+. All chemicals were reagent grade or better.
- Electrophoresis reagents were purchased from Bio-Rad Inc., Richmond, CA. ⁇ -32P dTTP (3000 Ci/mmol; 10 mCi/ml) was purchased from New England Nuclear Corp., Boston, MA.
- Table III summarizes the densitometry data obtained from an analysis of the gel autoradiogram. A comparison is also shown in this Table between the values observed for the relative peak intensities and those expected theoretically.
- a repeating polydeoxynucleotide of sequence: and an oligodeoxynucleotide of sequence 5′ CGGCCAGTGAATTCGGA 3′ (17 mer) were synthesized by the phosphoramidite method.
- a portion of the 17 mer (50 ng, 8.9 pmoles) was radioactively labeled at the 5′ end with ⁇ -32P ATP(Lot #2387-299 NEN, 3000 Ci/mmole, 10 m Ci/ml) T4 polynucleotide kinase using standard methods (Maxam, A. and Gilbert, W. (1980) Methods in Enzymology 65 , 499) to follow the subsequent enzymatic reactions.
- the radioactive 17 mer was purified by NENSORB TM chromatography (DuPont/New England Nuclear) using the protocol provided by the supplier.
- reaction products were ethanol precipitated by the addition of 375 ⁇ l of 0.3 M Na Acetate (pH 5.4) and 1.1 ml ethanol (-20°C), followed by spinning at 15,000 g's for 30 minutes.
- the precipitated DNA was then resuspended in 25 ⁇ l of H2O and reprecipitated with 1 ml of 100% ethanol (4°C) and centrifugation as above. The supernatant was removed and the precipitated DNA pellet dried under vacuum.
- the reaction was allowed to proceed for 1 hour at 37°C. 1 ⁇ l of this reaction was analyzed by 20% polyacrylamide/8 M urea gel electrophoresis to confirm complete digestion of Eco RI restriction sites.
- the remainder of the reaction products (19 ⁇ l) was purified by NENSORB TM chromatography and evaporated to dryness.
- Bacteriophage M13mp19 replicative form DNA (Garisch-Perran, C., Vieira, J., and Messing, J. (1985) Gene 33 , 103-119) was digested (1.3 ⁇ g) with Eco RI restriction enzyme and frozen to inactivate the restriction enzyme. 135 ng of this linearized M13mp19 was added to the total Klenow polymerizatin/ Eco RI restriction products above, with 0.5 mM ATP, 1 unit of T4 DNA ligase (Bethesda Research Labs, Lot #51131), 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl2, and 10 mM dithiothreitol in a final reaction volume of 20 ⁇ l. Reaction was performed at 12°C for 18 hours.
- a 23 base long oligodeoxynucleotide primer of sequence 5′- GTAAAACGACGGCCAGTGAATTC -3′ was hybridized to the M13mp19 Dra I clone in a volume of 50 microliters.
- the total amount of primer in the hybridization was 0.021 pmoles; the total amount of M13mp19 Dra I clone was 2.1 pmoles.
- Hybridization was done under temperature and buffer conditions previously described.
- Oligodeoxyribonucleotide sequences 1 and 2 were synthesized by the phosphoramidite method and purified on denaturing polyacrylamide gels. Annealing of oligomers 1 and 2 creates a "primed" template from which a DNA polymerase can elongate oligomer 2 from its 3′ terminus using oligmer 1 sequence as template, thus synthesizing a double stranded DNA molecule. Oligomers 1 and 2 alone are not substrates for the restriction enzyme Mbo II (data not shown); but the double stranded product of annealed 1 + 2 + DNA polymerase + dGTP _ dATP contains seven Mbo II restriction sites. Complete Mbo II digestion of the double stranded product will, among other products, produce 15 mer repeats, each repeat of composition: 5′TTTTTTTTTCTTCTT3′ (a) 3′AAAAAAAAAAAGAAGAA5′ (B)
- Oligomers 1 and 2 were typically performed using 1 - 2 pmoles of 1, and with and without 5 - 10 fmoles of 2. Oligomers were annealed by incubating in 1.4X Tag buffer (10X Tag buffer is 0.5 M Tris, pH 8.5, 25°C; 01 M NaCl, 0.1 M MgCl2) for 3 min at 65°C, then allowed to slowly cool ( ⁇ 30 min) to ⁇ 37°C. dNTPs were then added, usually 0.5 nmoles dATP, 100 pmoles of dGTP, and 10 - 50 ⁇ Ci ⁇ -32P dATP of specific activity 200 - 800 Ci/mmole.
- 1.4X Tag buffer 10X Tag buffer is 0.5 M Tris, pH 8.5, 25°C; 01 M NaCl, 0.1 M MgCl2
- dNTPs were then added, usually 0.5 nmoles dATP, 100 pmoles of dGTP, and 10 - 50 ⁇ Ci ⁇ -
- Final specific activity of ⁇ -32P dATP in these reactions is typically 5 - 10 Ci/mmole, and final Taq buffer concentration was 1X in a volume of 50 ⁇ L.
- Eppendorf 1.5-mL reaction tubes were incubated for 5 min at 65°C, 5 min at 37°C, then five units of Mbo II (0.5 ⁇ L) restriction enzyme was added. Incubations were continued for another 10 min to allow digestion, then the above temperature regimen was repeated, except Taq polymerase was not added again, and MboII enzyme was added every other 20-min cycle. Products were analyzed by TCA (10% trichloroacetic acid) precipitation and/or denaturing gel electrophoresis.
- Taq DNA polymerase was purchased from Perkin-Elmer Cetus and Mbo II restriction enzyme from Pharmacia.
- the polynucleotide sequence shown below (which may be prepared by standard techniques) was cloned into BamHI and EcoRI restriction enzyme linearized M13mp18 bacteriophage RF (commercially awaitable, for example from Bethesda) by standard methods. Bacteriophage containing the single stranded circular genome with the cloned insert were isolated from the infected, plaque purified, E . coli JM 101 host cells. DNA isolated from these bacteriophage proved to have the expected sequence and orientation of the DNA insert, namely the "TTCTTC(T)9" repeat orientation. This bacteriophage DNA is not a subtrate for Mbo II restriction enzyme (data now shown).
- Oligomer 3 5′GGTCGACTCTAGAGGATCCCCGGG 3′ was synthesized by standard phosphoramidite chemistries. This DNA will act as a "primer” and hybridize across a portion of the M13mp18 DNA sequence flanking sequence as well as a short region of the insert.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- Nucleic acid hybridization has been employed for investigating the identity and establishing the presence of nucleic acids. Hybridization is based on complementary base pairing. When complementary single stranded nucleic acids are incubated together, the complementary base sequences pair to form double stranded hybrid molecules. The ability of single stranded deoxyribonucleic acid (ssDNA) or ribonucleic acid (RNA) to form a hydrogen bonded structure with a complementary nucleic acid sequence has been employed as an analytical tool in molecular biology research. The availability of radioactive nucleoside triphosphates of high specific activity and the ³²P labelling of DNA with T4 kinase has made it possible to identify, isolate, and characterize various nucleic acid sequences of biological interest. Nucleic acid hybridization has great potential in diagnosing disease states associated with unique nucleic acid sequences. These unique nucleic acid sequences may result from genetic or environmental change in DNA by insertions, deletions, point mutations, or by acquiring foreign DNA or RNA by means of infection by bacteria, molds, fungi, and viruses. Nucleic acid hybridization has, until now, been employed primarily in academic and industrial molecular biology laboratories. The application of nucleic acid hybridization as a diagnostic tool in clinical medicine is limited because of the frequently very low concentrations of disease related DNA or RNA present in a patient's body fluid and the unavailability of a sufficiently sensitive method of nucleic acid hybridization analysis.
- Current methods for detecting specific nucleic acid sequences generally involve immobilization of the target nucleic acid on a solid support such as nitrocellulose paper, cellulose paper, diazotized paper, or a nylon membrane. After the target nucleic acid is fixed on the support, the support is contacted with a suitably labelled probe nucleic acid for about two to forty-eight hours. After the above time period, the solid support is washed several times at a controlled temperature to remove unhybridized probe. The support is then dried and the hybridized material is detected by autoradiography or by spectrometric methods.
- When very low concentrations must be detected, the current methods are slow and labor intensive, and nonisotopic labels that are less readily detected than radiolabels are frequently not suitable. A method for increasing the sensitivity to permit the use of simple, rapid, nonisotopic, homogeneous or heterogeneous methods for detecting nucleic acid sequences is therefore desirable.
- Recently, a method for the enzymatic amplification of specific segments of DNA known as the polymerase chain reaction (PCR) method has been described. This in vitro amplification procedure is based on repeated cycles of denaturation, oligonucleotide primer annealing, and primer extension by thermophilic polymerase, resulting in the exponential increase in copies of the region flanked by the primers. The PCR primers, which anneal to opposite strands of the DNA, are positioned so that the polymerase catalyzed extension product of one primer can serve as a template strand for the other, leading to the accumulation of a discrete fragment whose length is defined by the distance between the 5′ ends of the oligonucleotide primers.
- A process for amplifying, detecting and/or cloning nucleic acid sequences is disclosed in European Patent Applications 0 200 362 and 0 201 184. Sequence polymerization by polymerase chain reaction is described by Saiki, et al., (1986) Science, 230: 1350-1354. A method of making an oligonucleotide is described in European Patent Application No. 0194545. Belgian Patent No. 904402 discloses a mold for making DNA detection probes. Gene amplification in eukaryotic cells is disclosed in U.S. Patent No. 4,656,134.
- Langer, et al., Proc. Natl. Acad. Sci. USA, (1981) 78: 6633-6637 discloses the enzymatic synthesis of biotin labelled polynucleotides and the use of these materials as novel nucleic acid affinity probes. The detection of viral genomes in cultured cells and paraffin imbedded tissue sections using biotin labelled hybridization probes is discussed by Brigati, et al., Virology, (1983) 126: 32-50. U.S. Patent No. 4,486,539 discloses the detection of microbial nucleic acids by a one step sandwich hybridization test. Sensitive tests for malignancies based on DNA detection is described in U.S. Patent No. 4,490,472. U.S. Patent No. 4,480,040 discloses the sensitive and rapid diagnosis of plant viroid diseases and viruses employing radioactively labelled DNA that is complementary to the viroid or to the nucleic acid of the virus being diagnosed. European Patent Application 97373 (83106112.2) (Priority U.S. Patent Application 391,440 filed June 23, 1982) teaches modified labelled nucleotides and polynucleotides and methods of preparing, utilizing, and detecting the same. Methods and compositions for the detection and determination of cellular DNA are disclosed in U.S. Patent No. 4,423,153. Specific DNA probes in diagnostic microbiology are discussed in U.S. Patent No. 4,358,535. A method for detection of polymorphic restriction sites and nucleic acid sequences is discussed in European Patent Application No. 0164054. U.S. Patent No. 4,663,283 describes a method of altering double-stranded DNA.
- The invention disclosed herein includes methods and reagents for producing multiple copies of a primary polynucleotide sequence. This process can be initiated by the presence of a target polynucleotide sequence located at the 3′ terminus of a polynucleotide. The method comprises: (a) forming in the presence of nucleoside triphosphates and template-dependent polynucleotide polymerase an extension of a primary polynucleotide sequence hybridized with a template sequence of a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more cleavable sites (such as site specific cleavage sequences), (b) cleaving into fragments the extension at cleavable sites (such as polynucleotide sequences) in the presence of means for specifically cleaving the cleavable sites (such as polynucleotide sequences) when the extension is hybridized with the template sequence (for example with site specific cleavage sequences therein), (c) dissociating the fragments, (d) hybridizing the fragments with single stranded pattern polynucleotide, and repeating steps (a)-(d) above. Steps (a)-(d) can be conducted simultaneously or wholly or partially sequentially.
- The method and reagents have application in facilitating the determination of the presence of a polynucleotide analyte containing a target polynucleotide sequence in a sample suspected of containing such polynucleotide analyte. The target polynucleotide sequence can be DNA or RNA. In the analytical method, the target sequence is cut, e.g., by enzymes to provide a free 3′-OH when it does not already terminate in a 3′-OH. The target sequence is dissociated from any complementary nucleic acid and hybridized to a complementary binding sequence located at the 3′ end of two or more template sequences in the single stranded pattern polynucleotide. Chain extension of the target sequence with nucleoside triphosphates and template dependent polynucleotide polymerase and cleavage of the cleavable polynucleotide sequence in the extension provides the primary polynucleotide sequences in this invention.
- The invention further includes compositions for carrying out the above methods. One composition is a single stranded pattern polynucleotide that comprises an oligomer consisting of three to one-thousand monomeric units each consisting of an oligonucleotide template having from about eight to one-hundred bases and at least one restriction site. The monomeric units are preferably but need not be identical. The oligomer may be substituted at the 3′-end with a binding sequence complementary to a target sequence, and the 3′-terminal nucleotide will preferably be substituted by a chemical functionality that prevents a chain extension reaction with a template dependent polynucleotide polymerase. Alternatively, the single stranded pattern polynucleotide may be a ring. When the present method and compositions are utilized to determine the presence of a polynucleotide analyte in a sample, the cleaved fragments are detected by any means for detecting DNA fragments. The presence of the fragment or a complementary fragment indicates the presence of the polynucleotide analyte in the sample.
-
- FIG. 1 depicts a method for obtaining multiple copies of a primary polynucleotide sequence in accordance with the present invention.
- FIG. 2 depicts a method for effecting formation of a primary polynucleotide sequence in response to the presence of a polynucleotide analyte in accordance with the present invention.
- FIGS. 3-6 depict alternative methods for effecting formation of a primary polynucleotide sequence by the presence of a polynucleotide analyte.
- The present method allows the production of multiple copies of a primary polynucleotide sequence. The formation of the primary polynucleotide sequence can be initiated by the presence of a target polynucleotide sequence located at the 3′-terminus of a polynucleotide and is useful in detection of such a target sequence. The target polynucleotide sequence may be present in a polynucleotide analyte in a sample suspected of containing the analyte. The primary polynucleotide sequence may be the same as, but is preferably different from, the target polynucleotide sequence. In the production of multiple copies of a primary polynucleotide sequence the following components are provided: (i) the primary polynucleotide sequence, (ii) a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more site specific cleavage sequences, (iii) nucleoside triphosphates, (iv) template-dependent polynucleotide polymerase, and (v) means for specifically cleaving cleavable polynucleotide sequences when an extension of the primary polynucleotide sequence is hybridized with the site specific cleavage sequences. The template sequence is complementary to and can hybridize with the primary polynucleotide sequence. The complex of the primary polynucleotide sequence with the single stranded pattern polynucleotide is incubated either simultaneously or wholly or partially sequentially with remaining components under conditions for either simultaneously or wholly or partially sequentially forming the extension of the primary polynucleotide sequence comprising one or more copies of the primary polynucleotide sequence connected through the cleavable polynucleotide sequences, cleaving the extension into fragments at the cleavable polynucleotide sequences, dissociating the complex of the template sequence and the cleaved primary polynucleotide sequence which is identical with the primary polynucleotide sequence, and reforming the complex of the primary polynucleotide sequence with the single stranded pattern polynucleotide which is usually in excess. The above steps are repeated until the desired number of copies are obtained.
- The target polynucleotide sequence can be part of a polynucleotide analyte that is to be detected. One aspect of the invention comprises a determination of such a polynucleotide analyte by causing the target polynucleotide sequence to initiate the above described method for producing multiple copies. In this method the target polynucleotide sequence in the polynucleotide analyte is caused to terminate in a 3′ hydroxyl group when it is not already so terminated. This is usually effected by incubation with a restriction endonuclease. The target sequence is dissociated from complementary polynucleotides and caused to hybridize with the single stranded pattern polynucleotide which has a complementary binding polynucleotide sequence bound at the 3′ end of the template sequence. The formation of multiple copies of the primary polynucleotide sequence is then carried out by an extension of the target sequence along the single stranded pattern polynucleotide and cleavage of the extension into fragments as described above for the hybrid of the primary polynucleotide sequence with the single stranded pattern polynucleotide. The cleaved fragments are detected, and their presence indicates the presence of the polynucleotide analyte in the sample. The hybridization, chain extension, and cleaving can be repeated until the single stranded polynucleotide or nucleoside triphosphates are exhausted or the template-dependent polynucleotide polymerase becomes inactive, but will preferably not be repeated after the ratio of the cleaved fragments induced by the target polynucleotide sequence to those non-specifically induced ceases to increase. The present method has application to the detection of both DNA and RNA sequences.
- One composition of the present invention is a single stranded pattern polynucleotide that comprises an oligomer consisting of three to one-hundred monomeric units. Each monomeric unit consists of an identical oligodeoxynucleotide template having from about eight to one hundred, preferably 10 to 100, bases and at least one restriction site. Preferably, the oligomer is substituted at the 3′ end by a binding polynucleotide sequence of 15 or more bases that is complementary to a target polynucleotide sequence. The single stranded pattern polynucleotide is substituted at the 3′ end with a chemical functionality that prevents chain extension with a template dependent polynucleotide polymerase, or is cyclic.
- Before proceeding further with a description of the specific embodiments of the present invention, a number of terms will be defined.
- Polynucleotide analyte--a compound or composition to be measured which is a polymeric nucleotide having about 20 to 500,000 or more nucleotides, usually about 100 to 200,000 nucleotides, more frequently 500 to 15,000 nucleotides. The polynucleotide analytes include nucleic acids from any source in purified or unpurified form including DNA (dsDNA and ssDNA) and RNA, including t-RNA, m-RNA, r-RNA, mitochondrial DNA and RNA, chloroplast DNA and RNA, DNA-RNA hybrids, or mixtures thereof, genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and fragments thereof, and the like. The polynucleotide analyte can be only a minor fraction of a complex mixture such as a biological sample. The analyte can be obtained from various biological material by procedures well known in the art. Some examples of such biological material by way of illustration and not limitation are disclosed in Table I below.
- The polynucleotide analyte, where appropriate, will be treated to cleave the analyte to obtain a fragment that contains a target polynucleotide sequence located at the 3′ end of a polynucleotide. Accordingly, the analyte can be cleaved by known techniques such as treatment with a restriction endonuclease or other site specific chemical cleavage methods. Such treatment must produce a terminal 3′-hydroxy group or a group convertible to a 3′-hydroxyl group.
- For purposes of this invention, the cleaved fragment obtained from the polynucleotide analyte will usually be at least partially denatured or single stranded or treated to render it denatured or single stranded. Such treatments are well known in the art and include, for instance, heat or alkali treatment. For example, double stranded DNA can be heated at 90-100° C. for a period of about 1 to 10 minutes to produce denatured material.
- Target polynucleotide sequence -- at least a portion of a sequence of nucleotides to be identified, the identity of which is known to an extent sufficient to allow preparation of a binding polynucleotide sequence that is complementary to and will hybridize with such target sequence. The target polynucleotide sequence usually will contain from about 12 to 1000 or more nucleotides, preferably 15 to 50 nucleotides. The target polynucleotide sequence terminates or can be caused to terminate in a 3′-hydroxyl group and is frequently a part of the polynucleotide analyte. The target polynucleotide sequence will generally be a fraction of a larger molecule or it may be substantially the entire molecule. The minimum number of nucleotides in the target polynucleotide sequence will be selected to assure that the presence of polynucleotide analyte in a sample will provide at least double the number of copies of target polynucleotide sequence that would be expected to occur by chance in a sample that does not contain the polynucleotide analyte. In general, the number of copies expected to occur by chance will be LG/4n although the frequency of occurrence of a specific sequence in a sample may be greater or less than expected by chance. In this expression n is the number of nucleotides in the target polynucleotide sequence, L is the number of base pairs in the genome of the biologic source of the sample, and G is the number of genomic copies present in the sample. The maximum number of nucleotides in the target sequence will normally be governed by the length of the polynucleotide analyte and its tendency to be broken by shearing, by endogenous nucleases or by reagents used to cleave the target sequence.
- The target polynucleotide sequence will normally be part of the polynucleotide analyte. When not part of the analyte, the target polynucleotide sequence will be provided as part of a polynucleotide at a location other than at the 3′ end of the polynucleotide. The presence of the polynucleotide analyte will then cause the target sequence to be cut causing it to terminate at the 3′ end. For example, the polynucleotide analyte can be RNA that can be hybridized with a complementary single stranded primer polynucleotide containing the target polynucleotide sequence that includes a cleavage site. The hybridized RNA: primer molecule can be treated with a cleavage agent such as a restriction endonuclease capable of cutting heteroduplexes and then denatured to provide a single stranded target sequence terminating in a 3′-OH group.
- Primary polynucleotide sequence -- a polynucleotide sequence that can be the same as or different from the target polynucleotide sequence and will usually be different. The primary polynucleotide sequence is complementary to the template sequence. It will normally be a sequence of eight to 100 bases, usually DNA, preferably 10-75 bases, more preferably 12-50 bases. Frequently, the primary polynucleotide sequence will contain derivatized nucleotides, and it will preferably consist of only two or three of the four nucleotides A and dA or derivatives thereof, U and dT or derivatives thereof, C and dC and derivatives thereof, and G and dG or derivatives thereof . Multiple copies of the primary polynucleotide sequence will be produced in the present method as a result of the presence of the target polynucleotide sequence.
- Single stranded pattern polynucleotide -- a natural or synthetic sequence of nucleotides that is capable of hybridizing with the primary polynucleotide sequence. The single stranded pattern polynucleotide comprises an oligomer of two or more template sequences, preferably two or more copies, preferably at least three, of a template sequence, preferably identical, each containing one or more cleavable sites such as site specific cleavage sequences. The template sequence can contain two or three, preferably three, members selected from the group comprising nucleotides, deoxynucleotides, and derivatives thereof. For example, the template sequence can preferably consist of only three of the four nucleotides A and dA or derivatives thereof, U and dT or derivatives thereof, C and dC or derivatives thereof, and G and dG or derivatives thereof. The template sequence is complementary to the primary polynucleotide sequence. The oligomer can be attached at its 3′ end directly or through intermediate nucleotides to the 5′ end of a binding polynucleotide sequence complementary or substantially complementary to the target polynucleotide sequence. Usually, the attachment of the oligomer to the binding polynucleotide sequence will be through one or more site specific cleavage sequences. When the oligomer is bound to the binding polynucleotide sequence through intermediate nucleotides and consists of only two or three bases, the intermediate nucleotides will also be selected from those bases. The single stranded pattern polynucleotide can also contain nucleotides other than those in the binding polynucleotide sequence and the template sequences as long as such nucleotides do not interfere with the present method. Such other nucleotides would usually be outside the binding polynucleotide sequence and the oligomer.
- The single stranded pattern polynucleotide will usually contain from 36 to 4,000 nucleotides, preferably 80 to 1,000 nucleotides and will preferably contain 3 to 100, more preferably 6 to 50, template polynucleotide sequences. The single stranded pattern polynucleotide can be DNA or RNA, preferably DNA, and can be linear or circular, preferably circular. It can be a synthetic oligonucleotide or constructed from a virus, plasmid, or the like. When not cyclic it will usually be terminated at its 3′ end by a group that will interefere with chain extension by nucleic acid polymerases.
- A critical feature of the single stranded pattern polynucleotide sequence is that it be free from any polynucleotide sequence that is either complementary or can form an extension along the single stranded pattern polynucleotide sequence that is complementary to the template or binding polynucleotide sequences. Furthermore, where the single stranded pattern polynucleotide sequence is non-cyclic, it is preferably terminated at the 3′ end with a group incapable of reacting in a chain extension reaction sequence by template-dependent polynucleotide polymerase. In this way random initiation of chain extension along the template is prevented. Exemplary of such a group, by way of illustration and not limitation, are dideoxynucleotides, such as dideoxythymidine, dideoxyadenosine, dideoxyguanosine, and dideoxycytidine, isopropylphosphoryl, phosphate, N-(trimethyl ammonium ethyl) carbamoyl, polysaccharides such as dextran, polystyrene, hydrazones, proteins, and deoxyribose-3′-phosphoryl and the like.
- Dideoxynucleotide capping can be carried out according to conventional techniques such as, described by Atkinson, et al. (1969) Biochem., 8: 4897-4904. Hydrazone formation can be obtained by oxidation of a ribonucleotide at the 3′ end with periodate to form a dialdehyde, which can then react with substituted hydrazines such as dinitrophenylhydrazine, positively charged hydrazines such as 2-trimethylammonium-1-ethylhydrazine, hydrazines bonded to dextran and proteins, particularly hydrazide derivatives of carboxyalkyldetrans and proteins, etc., and the like. Such 3′ blocked material may then be separated from other reaction mixture components by affinity chomatography and other techniques well known in the art. Aldehyde formation followed by derivatization of the aldehyde is one general procedure for blocking the 3′ end of the template. See, for example, Reines, et al. (1974) Nucleic Acids Research, 1:767-786. A 3′-terminal phosphate group can be achieved, for example, by treating the single stranded polynucleotide terminated with a ribonucleotide with periodate and β-elimination by cyclohexylamine or benzylamine (See Krynetskaya et al. (1986) Nucleosides and Nucleotides, 5(1): 33-43 or by T4 RNA ligase addition of pCp (3′,5′-diphosphate cytidine) such as is typically carried out in the 3′ end labelling of DNA.
- Terminal 3′ blocking may also be achieved by covalent attachment of the 3′ end to a glass bead, resin, or any other suitably modified particle or bead. This means of blocking the 3′ functionality is commonly practiced under a number of forms in the synthesis of oligonucleotides.
- A specific embodiment of a single stranded pattern polynucleotide that can be utilized in the present invention is one in which the oligomer consists of only three nucleotide members selected from the group consisting of dA, dC, dG and dT or derivatives of these nucleotide members that have similar complementarity of binding to nucleotide bases as the parent member and do not interfere with template dependent polynucleotide polymerases, when incorporated in the template polynucleotide sequence.
- The single stranded pattern polynucleotide can be obtained by cloning or synthesis. Synthetic procedures and isolation methods can be automated or not. Such methods include phosphotriester and phosphodiester methods (Narang, et al. (1979) Meth. Enzymol 68:90) and synthesis on a support (Beaucage, et al. (1981) Tetrahedron letters 22:1859-1862) as well as the phosphoramidite technique and others described in "Synthesis and Applications of DNA and RNA," S.A. Narang, editor, Academic Press, New York, 1987, and the references contained therein.
- The single stranded pattern polynucleotide often comprises 5 to 50 template sequences connected by one or more site specific cleavage sequences.
- Template sequence -- a sequence of nucleotides, at least one of which is complementary to the primary polynucleotide sequence, located within the single stranded pattern polynucleotide and present usually as a tandem repeat including one or more cleavable sites such as site specific cleavage sequences. The number of nucleotides in the template sequence should be sufficiently high that stringency conditions used to hybridize with the primary polynucleotide sequence will prevent excessive random non-specific hybridization and not so high that the conditions needed to dissociate the template sequence from the primary polynucleotide sequence will inactivate the template dependent polynucleotide polymerase. Usually, the number of nucleotides in the template sequence is from 8 to 100, preferably, 10 to 75, more preferably, 12 to 30. 10 to 20 is also a very useful number. Usually, from about three to 100 copies of the template sequence are present in the single stranded pattern polynucleotide.
- Site specific cleavage sequence -- a sequence of nucleotides in a polynucleotide that, when complexed with a complementary polynucleotide having a cleavable polynucleotide sequence, will promote cleavage of such complementary cleavable polynucleotide sequence at a specific site within the sequence. An additional reagent will usually be required for cleavage. The site specific cleavage sequence will usually consist of 4 to 30 nucleotides, more usually 4 to 15 nucleotides, preferably 4 to 8 nucleotides. Normally, the complex of the site specific cleavage sequence and the polynucleotide having the cleavable polynucleotide sequence will comprise a restriction endonuclease site and the additional reagent will be a restriction endonuclease.
- Type I restriction endonucleases recognize a specific nucleotide sequence and make a cut nearby, without any specificity as to the nucleotide sequence that is cut. Consequently, utilization of a cleavage promoting sequence recognized by a Type I restriction endonuclease would require the use of a second reagent or the presence of a derivatized nucleotide in the site specific cleavage sequence that would provide for cleavage at a specific site. Type II restriction endonucleases recognize a specific sequence and make a double strand cut at a fixed point within that sequence. Such sequences usually have a central axis of symmetry and read identically in both directions from that axis. Type II restriction endonucleases are of most general utility in the method of the invention. Type III restriction enzymes recognize asymmetric restriction sites that are a specific sequence and make a double strand cut at a fixed point some number of nucleotides to the side of such sequence. Type III enzymes are therefore also of use in this method.
-
- The site specific cleavage sequence will frequently be cut but is not required to be cut during the method of the present invention as long as the reagent required for cleavage is capable of cleaving a cleavable polynucleotide sequence in a polynucleotide that is complementary and bound to the specific cleavage sequence. Exemplary of such a site specific cleavage sequence is a methylated sequence corresponding to one of those given above in Table II. Methylation of the site specific cleavage sequences of the single stranded pattern polynucleotide can be achieved by introducing a methylated nucleotide in the synthesis of the single stranded pattern polynucleotide or by using an enzyme such as methyl transferase, or the like. To achieve cleavage of the sequence complementary to the site specific cleavage sequence of the single stranded pattern polynucleotide after chain extension in accordance with the present method, a cleaving agent that recognizes and cleaves hemi-methylated sites is employed. For example, an enzyme such as Taq I which can cut the unmethylated strand of TCG⁹6mA/TCGA duplexes or Sau 3AI, MspI, AccI or Xho II or the like can be employed. Nelson and McClelland (1987) Nucleic Acids Res. 15, r219-r230 and the references contained therein. Another example of a cleavable sequence formed during the method of the invention is a DNA sequence produced utilizing an RNA template sequence or a RNA sequence produced utilizing a DNA template sequence wherein the cleaving agent cleaves only RNA or DNA, a DNA/RNA hybrid, as the case may be. Cleavage of DNA and possibly RNA also in a DNA:RNA hybrid has been described by Molloy and Symms (1980) Nucleic Acids Res. 8, 2939-2946.
- Often site specific cleavage sequences contained in template sequences are all identical.
- Nucleoside triphosphates -- a nucleoside having a 5′ triphosphate substituent, usually a deoxynucleoside triphosphate. The nucleosides are pentose sugar derivatives of nitrogenous bases of either purine or pyrimidine derivation, covalently bonded to the 1′-carbon of the pentose sugar. The purine bases include adenine(A), guanine(G), and derivatives and analogs thereof. The pyrimidine bases include cytosine (C), thymine (T), uracil (U), and derivatives and analogs thereof. Often the deoxynucleotide triphosphates are dATP, dGTP, dCTP and dTTP, more often three members of this group or derivatives thereof.
- The derivatives and analogs are exemplified by those that are recognized and polymerized in a similar manner to the underivatized nucleotide triphosphates. Examples of such derivatives or analogs by way of illustration and not limitation are those which are modified with a reporter group, biotinylated, amine modified, radiolabeled, alkylated, and the like and also include thiophosphate, phosphite, ring atom modified derivatives, and the like. The reporter group can be a fluorescent group such as fluoroscein, a chemiluminescent group such as luminol, a terbium chelator such as N-(hydroxyethyl) ethylenediaminetriacetic acid that is capable of detection by delayed fluorescence, and the like. Suitably the reporter group is selected from the group consisting of biotin, fluorescers, chemiluminescers, and small organic molecules.
- Template-dependent polynucleotide polymerase (TDPP)-- a catalyst, usually an enzyme, for forming an extension of the primary polynucleotide sequence or the target polynucleotide sequence, as the case may be, along the single stranded pattern polynucleotide where the extension is complementary to the template sequence. The template-dependent polynucleotide polymerase utilizes the nucleoside triphosphates as the building blocks for the extension which proceeds in a 5′ to 3′ (3′ to 5′ with respect to the template) direction until extension terminates. Usually, the catalysts are enzymes, such as RNA polymerases, preferably DNA polymerases such as, for example, prokaryotic DNA polymerase (I, II, or III), T4 DNA polymerase, T7 DNA polymerase, Klenow fragment, reverse transcriptase, RNA replicases, and the like derived from any source such as cells, bacteria, such as E. coli, plants, animals, virus, thermophilic bacteria, and so forth.
- Means for specifically cleaving a cleavable site, such as a polynucleotide sequence when the cleavable polynucleotide sequence is hybridized with a complementary polynucleotide having a site specific cleavage sequence -- usually a catalyst. When the cleavable polynucleotide sequence is a restriction endonuclease recognition site, such means is usually a restriction endonuclease, which is an enzyme capable of cutting double strand DNA at or near a particular nucleotide sequence. Such means can also be a chemical compound that specifically reacts with a base resulting in cleavage. See, for example, Peter Dervan (1986) Science 232:464-471. Cleavage of a specific sequence may also be achieved by incorporating in the site specific cleavage sequences a cleavage promoting group such as a chelate iron atom or a photoactivator.
- Wholly or partially sequentially -- when the sample and various agents utilized in the present invention are combined other than simultaneously, one or more may be combined with one or more of the remaining agents to form a subcombination. Each subcombination can then be subjected to one or more steps of the present method. Thus, each of the subcombinations can be incubated under conditions to achieve one or more of the desired results.
- One embodiment of the method of the present invention is directed to the production of multiple copies of a primary polynucleotide sequence as the result of the presence of a target polynucleotide sequence substantially identical to the primary polynucleotide sequence located at the 3′ terminus of a polynucleotide. A combination is prepared either wholly or partially sequentially or simultaneously comprising the target polynucleotide sequence, single stranded pattern polynucleotide, nucleotide triphosphates, template-dependent polynucleotide polymerase, and means for specifically cleaving cleavable polynucleotide sequences. The combination is incubated under conditions for either wholly or partially sequentially or simultaneously hybridizing the target sequence with single stranded pattern polynucleotide, forming a chain extension of the target sequence comprising one or more copies of a polynucleotide sequence complementary to the template sequence connected through cleavable polynucleotide sequences, cleaving the extension into fragments at the cleavable polynucleotide sequences, denaturing the fragments, hybridizing the fragments with single stranded pattern polynucleotide, and forming a chain extension of the hybridized fragment. The above steps are repeated until the desired number of copies is obtained.
- One method (A) for obtaining multiple copies of a primary polynucleotide sequence is represented in FIG. 1.
- The single stranded pattern polynucleotide (1) comprised of repeating template sequences (1a) containing restriction endonuclease sites (Δ) is incubated with the primary polynucleotide sequence (2) under temperature and solvent conditions suitable for at least partial hybridization of (1) and (2) to form a duplex (3) in which the 3′-OH of (2) corresponds to the cleavage point in the restriction endonuclease site. Preferably, under the same conditions, duplex (3) reacts with nucleotide triphosphates (NT) by catalysis with template dependent polynucleotide polymerase (TDPP) to extend the primary polynucleotide sequence (2) to form the extended duplex (4). Under preferably the same conditions duplex (4) reacts with a restriction endonuclease (RE) to form duplex fragments (5) consisting of the template sequence (1a) and the primary polynucleotide sequence (2). Duplex fragments (5) dissociate to give multiple copies of the single stranded primary polynucleotide sequence (2) which reenter the cycle.
- In this method the single stranded pattern polynucleotide (1) can also include nucleotide sequences bound to its 3′ and 5′ ends, and these sequences may be connected to form a ring. Usually, when additional sequences are bound to the single stranded pattern polynucleotide, the repeating template sequences will be made up of only two or three, preferably three, of the four natural nucleotides, dA or A, dT or U, or dG or G, and dC or C, or derivatives thereof. Under this circumstance only the two or three corresponding complementary nucleotide triphosphates or derivatives thereof are included in the polymerization reaction.
- A method for analyzing for a polynucleotide analyte involves causing the analyte to effect formation of primary polynucleotide sequence from which multiples can be formed by the method of this invention and detecting these copies. One method (B) for effecting forming of a primary polynucleotide sequence by the polynucleotide analyte is depicted in FIG. 2.
- A polynucleotide analyte (6) containing a target polynucleotide sequence (6a) is denatured and then hybridized with excess single stranded pattern polynucleotide (1) having a portion of its template sequence (1a) complementary to the target polynucleotide sequence (6a). The resulting hybrid (7) is then treated with a restriction enzyme (RE) to form a free hydroxy at the 3′ end of the target polynucleotide sequence (6b). This target polynucleotide sequence, which forms as a duplex (8) with at least a portion of the single stranded pattern polynucleotide (1), is dissociated from the duplex (8) and is hybridized to another molecule of single stranded pattern polynucleotide (1) to form the new duplex (9). The duplex (9) reacts with nucleoside triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend target polynucleotide sequence (6b) and form an extended duplex (10). Under preferably the same conditions, duplex (10) reacts with a restriction endonuclease (RE) to form duplex fragments (5) which can dissociate into primary polynucleotide sequence (2) as illustrated in method (A).
- Another method (C) for effecting formation of a primary polynucleotide sequence by the presence of a polynucleotide analyte is depicted in FIG. 3.
- The polynucleotide analyte (6) is first treated with a restriction enzyme (RE) that cuts the target polynucleotide sequence (6a) to produce duplex (11) containing the target polynucleotide sequence (6b) terminating in a 3′-hydroxy group. This duplex is then dissociated, and the cleaved target polynucleotide sequence is hybridized with excess single stranded pattern polynucleotide (1) to form duplex (9). Duplex (9) is extended according to method (B) for forming a primary polynucleotide sequence.
- In another method (D) (see FIG. 4) for effecting formation of a primary polynucleotide sequence by the presence of a polynucleotide analyte, duplex (11) is dissociated and rehybridized with a single standed pattern polynucleotide (12) which contains at least one template sequence (1a) and a binding polynucleotide sequence (12a) at its 3′ end that is complementary to target sequence (6b). Preferably, (12) is cyclic and in no case can it be susceptible to chain extension by template dependent polynucleotide polymerase in the absence of a cleavage agent.
- The resulting duplex (13) reacts with nucleotide triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend the target polynucleotide sequence (6b) to form the extended duplex (14). Duplex (14) reacts with a restriction enzyme (RE) to form duplex fragments (5) which can dissociate into primary polynucleotide sequence (2) as illustrated in method (A). When single stranded pattern polynucleotide (12) contains only one template sequence (1a), it will be necessary to include single stranded pattern polynucleotide (1) that contains at least two template sequences in order to form multiple copies of the primary polynucleotide sequence according to method (A).
- In still another method (E) (FIG. 5) for eliciting formation of a primary polynucleotide sequence by presence of a polynucleotide analyte, preferably an RNA analyte, (6′) having a sequence of polynucleotides to be identified (6a′), the analyte is dissociated into single strands, if it is not already single stranded. It is then hybridized with a primer polynucleotide (15) comprised of a primary polynucleotide sequence (2) with its 3′ end bound to a binding polynucleotide sequence (15a).
- After formation of hybrid (16), the hybrid is cut by a restriction enzyme to give the primary polynucleotide sequence (2) with a free 3′-OH suitable for formation of multiple copies according to method (A).
- Another method (F) (FIG. 6) for effecting formation of a primary polynucleotide sequence as a result of the presence of a polynucleotide analyte requires a single stranded pattern polynucleotide (18) comprised of a binding polynucleotide sequence (18a) connected at its 5′ end to an oligomer of template sequences (1a). A duplex (11) containing a target polynucleotide sequence (6b) ending in a 3′-hydroxyl is produced in response to the presence of a polynucleotide analyte according to Methods (B) or (C). The duplex is denatured and the sequence (6B) is hybridized with the single stranded pattern polynucleotide (18). The resulting hybrid (19) reacts with nucleotide triphosphates (NT) by catalysis with template-dependent polynucleotide polymerase (TDPP) to extend the target polynucleotide sequence (6b) and form an extended duplex (20). Duplex (20) reacts with a restriction endonuclease (RE) to form duplex fragments (5) which can dissociate into the primary polynucleotide sequence (2) as illustrated in Method (A). In addition duplex (21) is found which can dissociate and hybridize with single stranded pattern polynucleotide (18) to reform hybrid (19).
- In carrying out the method an aqueous medium will be employed. Other polar cosolvents may also be employed, usually oxygenated organic solvents of from 1-6, more usually from 1-4, carbon atoms, including alcohols, ethers and the like. Usually these cosolvents will be present in less than about 70 weight percent, more usually in less than about 30 weight percent.
- The pH for the medium will usually be in the range of about 4.5 to 9.5, more usually in the range of about 5.5 - 8.5, and preferably in the range of about 6 - 8. The pH and temperature are chosen and varied, as the case may be, so as to provide for either simultaneous or sequential hybridization of the target sequence with the single stranded pattern polynucleotide, extension of the target sequence, cleavage of the extension into fragments at the cleavable polynucleotide sequences, reversible denaturation of the fragments, hybridization the fragments with single stranded pattern polynucleotide, and extension of the hybridized fragments. In some instances, a compromise will be made between these considerations depending on whether the above steps are performed sequentially or simultaneously. Various buffers may be used to achieve the desired pH and maintain the pH during the determination. Illustrative buffers include borate, phosphate, carbonate, Tris, barbital and the like. The particular buffer employed is not critical to this invention but in individual methods one buffer may be preferred over another.
- Moderate temperatures are normally employed for carrying out the method and desirably constant temperatures during the period for conducting the method. A constant temperature will usually be selected near the melting temperature of the complex of primary polynucleotide sequence and the template sequence. The option to utilize a constant temperature is a benefit realized in the present method that arises because the length of the primary polynucleotide sequence and the newly formed copies thereof are identical. The temperatures for the method will generally range from about 20 to 90°C, more usually from about 30 to 70°C preferably 37 to 50°C. However, the temperature can be varied depending on whether the above steps are carried out sequentially or simultaneously. For example, relatively low temperatures of from about 20 to 40°C can be employed for the chain extension and cleavage steps, while denaturation and hybridization can be carried out at a temperature of from about 40 to 80°C.
- The time period for carrying out the method of the invention will generally be long enough to achieve a desired number of copies of the primary polynucleotide sequence. This, in turn, depends on the purpose for which the amplification is conducted, such as, for example, as assay for a polynucleotide analyte. Generally, the time period for conducting the method will be from about 5 to 200 min. As a matter of convenience it will usually be desirable to minimize the time period. In general, the time period for a given degree of amplification can be shortened, for example, by selecting concentrations of nucleoside triphosphates, sufficient to saturate the template dependent nucleotide polymerase and by increasing the concentrations of template-dependent polynucleotide polymerase. A particularly critical factor is the efficiency of the means to cleave site specific cleavage sequences. It will generally be desirable to select conditions that maximize the cleavage rates, for example, by use of a restriction enzyme having a high turn over and optimizing its concentration. Another critical factor in reducing the time period is the number of template sequences present in the single stranded pattern polynucleotide.
- Provided at least two template sequences are present, the number of copies of polynucleotide sequence that are formed will increase exponentially with each extension. Preferably, at least three template sequences are present whereupon the number of copies doubles with each extension of the primary polynucleotide sequence. More preferably at least five template sequences are present and the number of copies triples with each extension. In general the number of copies present after each extension should multiply by about (n+1)/2 where n is the number of template sequences in the single stranded pattern polynucleotide.
- The concentration of the target polynucleotide sequence which is to be copied can be as low as one or two molecules in a sample but will generally vary from about 10² to 10¹⁰, more usually from about 10³ to 10⁸. The concentration of the single stranded pattern polynucleotide sequence will usually depend on the number of copies desired, and the rate at which such copies are formed will normally determine the concentration of the other reagents and the number of template sequences in the single stranded pattern polynucleotides.
- The final concentration of each of the reagents will normally be determined empirically to optimize the number of the copies of the target sequence.
- The concentration of the single stranded pattern polynucleotide and the deoxynucleoside triphosphates in the medium can vary widely; preferably, these reagents are present in an excess amount. The deoxynucleoside triphosphates will usually be present in 10⁻⁶ to 10⁻²M, preferably 10⁻⁵ to 10⁻³M. The single stranded pattern polynucleotide will usually be present in at least 10⁻¹²M, preferably 10⁻¹⁰M, more preferably at least about 10⁻⁸M.
- The concentration of the template-dependent polynucleotide polymerase and the means for cleaving the cleavable site such as the site specific cleavable sequence, which is usually a restriction endonuclease and any cofactors thereof in the medium can also vary substantially. These reagents may be present in as low as 10⁻¹²M but may be present in a concentration at least as high or higher than the concentration of the single stranded pattern polynucleotide. The primary limiting factor being the cost of the reagents, which are usually enzymes.
- The order of combining of the various reagents to form the combination may vary. Generally, a target polynucleotide sequence located at the 3′ terminus of a polynucleotide is obtained. This may be combined with a pre-prepared combination of single stranded pattern polynucleotide sequence, nucleoside triphosphates, template-dependent polynucleotide polymerase, and cleaving agent. However, simultaneous addition of the above, as well as other step-wise or sequential orders of addition, may be employed.
- The concentration and order of addition of reagents and conditions for the method are governed generally by the desire to maximize the number of copies of the primary polynucleotide sequence and the rate at which such copies are formed.
- One aspect of the present invention concerns the determination or detection of a polynucleotide analyte terminating in, or caused to be terminated in, a 3′-hydroxy nucleotide. The polynucleotide analyte will generally be present in a sample suspected of containing the polynucleotide analyte. The method comprises providing in combination in an aqueous medium either sequentially or simultaneously one or more of the polynucleotide analyte, an exogeneously added single stranded pattern polynucleotide capable of hybridizing with the polynucleotide analyte, nucleoside triphosphates, and template-dependent polynucleotide polymerase. The medium is incubated under conditions for either sequentially or simultaneously hybridizing at least a target sequence in the polynucleotide analyte with single stranded pattern polynucleotide, forming an extension of the target sequence along the template, cleaving the extension into fragments, denaturing the fragments by hybridizing the fragments with single stranded pattern polynucleotide, and forming an extension of the fragments. The above steps are repeated under the reaction conditions until a detectible number of fragments are obtained. Thereafter, the fragments, or fragments complementary thereto, are detected and the presence of the fragments indicates the presence of the polynucleotide analyte in the sample.
- Prior to providing the combination, the sample can be incubated sequentially (1) with reagents for modifying the 3′ end of any polynucleotide in the sample to prevent free 3′ ends from reacting with the template-dependent polymerase and (2) with a restriction enzyme capable of producing a hydroxyl group at the 3′ end of the polynucleotide analyte to be determined. The reagents for modifying the 3′ end of a polynucleotide can comprise an enzyme capable of catalyzing the reaction of the
polynucleotide 3′-hydroxyl group. Examples of such an enzyme are polynucleotide ligases from any source such as E. coli bacteria ligase, T4 phage DNA ligase, mammalian DNA ligase, and the like, terminal deoxynucleotidyl transferases, T4 RNA ligase, and so forth. The ligases referred to above additionally can include an oligonucleotide terminated at the 3′ end with a group that does not react to provide chain extension by the template-dependent polynucleotide polymerase. The terminal transferase can include a dideoxynucleotide triphosphate, methylated nucleotide triphosphate, and the like. Such reagents and reactions are well known in the art for other applications and further detailed discussion is not necessary here. - The pH, temperature, solvent, and time considerations will be similar to those described above for the amplification method. Generally, conditions are chosen for either sequentially or simultaneously hybridizing the polynucleotide analyte with the single stranded pattern polynucleotide, forming an extension along the pattern polynucleotide, cleaving the extension into fragments, reversibly denaturing the fragments, hybridizing the fragments with single stranded pattern polynucleotide, and forming an extension of the fragments. The concentration of polynucleotide analyte which can be assayed will be similar to those described above for the concentration of the target polynucleotide sequence.
- While the concentrations of the various reagents will generally be determined by the concentration range of interest of the polynucleotide analyte, the final concentration of each of the reagents will normally be determined empirically to optimize the sensitivity of the assay over the range of interest. The concentration of the other reagents in an assay generally will be determined following the same principles as set forth above for the amplification methods. The primary consideration is that a sufficient number of copies of a primary polynucleotide sequence be produced in relation to the polynucleotide analyte sequence so that such copies can be readily detected and provide an accurate determination of the polynucleotide analyte.
- After the medium is incubated either simultaneously or sequentially under the above conditions any fragments present are detected. The presence of the fragments indicates the presence of the polynucleotide analyte in the sample. The fragments can be detected in numerous ways. Essentially any method for detection of nucleic acids can be utilized in detecting the fragments formed in the assay method in the present invention. Alternatively, any method for detection of pyrophosphate formed during the polymerization can be utilized. Any standard method for detecting double strand nucleic acid can be used such as, for example, precipitation of the single strand material with trichloracetic acid and measurement of light absorption of the solution, intercalating of a dye, such as ethidium bromide, and the like, followed by spectroscopic measurement, measurement of changes in hyperchromicity, optical rotation measurements, nucleic acid probe hybridization methods, and the like. Any of the above detection methods can be utilized in conjunction with a preliminary chromatographic separation step to separate double strand fragments the size of the hybridized or unhybridized primary polynucleotide sequence from higher and lower molecular weight material in the medium. The above procedures are well known in the art and will not be described in great detail but rather will be described in a summary fashion in the following paragraphs.
- On method for detecting nucleic acids is to employ nucleic acid probes. This method generally involves immobilization of the target nucleic acid on a solid support such as nitrocellulose paper, cellulose paper, diazotized paper, or a nylon membrane. After the target nucleic acid is fixed on the support, the support is contacted with a suitably labelled probe nucleic acid for about two to forty-eight hours. After the above time period, the solid support is washed several times at elevated temperatures to remove unbound probe. The support is then dried and the hybridized material is detected by autoradiography or by colorimetric methods.
- One method utilizing probes is described in U.S. Patent Application Serial No. 773,386, filed September 6, 1985, (European Patent Application Publication Number 0224995), the disclosure of which is incorporated herein by reference. The method comprises combining in an assay medium the sample and first and second polynucleotide reagents complementary to the nucleic acid fragment. Each of the first and second reagents hybridize with a different region of nucleic acid fragment. The first reagent contains means for rendering the first reagent non-covalently polymerizable. The second reagent contains means for rendering the second reagent detectable. The sample and the first and second reagents are combined in the assay medium under conditions for polymerizing the first reagent wherein the second reagent becomes bound to the polymerized first reagent only when the DNA fragment is present in the sample. A determination is then made as to whether the second reagent has become bound to the polymerized first reagent.
- In the present method, the primary polynucleotide sequence can be labeled with a ligand by having present a ligand substituted nucleotide triphosphate in the combination of reagents. The template sequence can be labeled with a second ligand. The complex of these two sequences that is formed in the method can be detected by causing the complex to bind to a surface to which is bound a receptor for one of the ligands. A receptor for the other ligand that is labeled with a detectable group such as an enzyme or fluorophore can then be caused to bind to the other ligand in proportion to the amount of the complex that binds to the surface.
- Another method for detecting the nucleic acid fragments involves dyes possessing an affinity for DNA or RNA. Exemplary of such dyes are DNA intercalating agents, which are generally well known compounds and are, for the most part, commercially available. Representative of such agents are acriflavine, acriflavine hydrochloride, and like acridine derivatives, and ethidium halides such as ethidium bromide.
- The above method can also be applied to the determination of the presence of an RNA analyte in a sample suspected of containing such RNA analyte. The RNA polynucleotide analyte is provided by combining in an aqueous medium the sample, a single stranded DNA primer comprising a deoxynucleic acid sequence containing a restriction site and capable of hybridizing with the RNA sequence, and a restriction enzyme capable of cleaving the primer at the restriction site when the primer is hybridized with the RNA sequence. The combination is incubated for a time sufficient to permit cleaving to occur under conditions for cleaving the hybridized primer at the restriction site. Such conditions are similar to those described above for cleaving the site specific cleavage sequences. The cleaved primer can then serve as the target sequence in the above method.
- The DNA primer can be cyclic or can be terminated at its 3′ end by a group incapable of reacting in a reaction catalyzed by the template-dependent polynucleotide polymerase.
- One embodiment of the present invention is a method of producing multiple polynucleotide molecules as a function of the presence of a target sequence of nucleotides in a polynucleotide sample. The method comprises combining the polynucleotide sample either simultaneously or wholly or partially sequentially with one or more of (1) means to cause the target sequence to terminate in a 3′ hydroxy group when the target sequence does not already terminate in such group, (2) single stranded pattern polynucleotide comprising a binding polynucleotide sequence complementary to substantially all of the target sequence and a site specific cleavage sequence joined at the 5′ end of the binding polynucleotide sequence wherein the 5′ end of the site specific cleavage sequence is joined to the 3′ end of the template sequence (4) nucleoside triphosphates, (5) template-dependent polynucleotide polymerase, and (6) means for cleaving the sequence complementary to the site specific cleavage sequences when hybridized with the site specific cleavage sequences. The combining is carried out under conditions which promote wholly or partially, either sequential or simultaneous denaturation of the target sequence when the target sequence is double stranded, hybridization of the target sequence with the template, extension of the target sequence by template-dependent polynucleotide polymerase to produce a duplex, cleavage of the extension in the duplex into fragments, denaturation of the duplex, hybridization of the fragments with single stranded pattern polynucleotide, and extension of the said fragments. The above steps are repeated until the desired number of copies is obtained.
- Another embodiment of the present invention is a method for determining the presence of a polynucleotide analyte in a sample suspected of containing said polynucleotide analyte. The method comprises combining in an aqueous medium either wholly or partially sequentially or simultaneously (1) said sample, (2) means for obtaining from the polynucleotide analyte a target sequence and for terminating the sequence in a 3′-OH group, (3) single stranded pattern polynucleotide comprised of a sequence complementary to the target sequence joined at its 5′ end to a multiply repeated sequence of at least 12 nucleotides, said repeated sequence, when hybridized to its complementary sequence and incubated with a restriction enzyme, promoting cleavage of the complementary sequence to form restriction fragments, (4) deoxynucleoside triphosphates, (5) a DNA dependent nucleotide polymerase for extending the target sequence to provide said complementary sequence, and (6) a restriction endonucleases for forming the restriction fragments. The combining is carried out under conditions for either wholly or partially sequentially or simultaneously obtaining the target sequence from the polynucleotide analyte, hybridizing the target sequence to the single stranded pattern oligonucleotide, extending the target sequence to form the complementary sequence, cleaving the complementary sequence into fragments, denaturing the hybridized duplex of the complementary sequence and the repeated sequence, hybridizing the fragments with single stranded pattern polynucleotide, and extending the fragments to form complementary sequences. The method further includes detecting cleaved complementary sequence. The presence of the cleaved complementary sequence indicates the presence of the polynucleotide analyte in said sample.
- Another embodiment of the present method is directed to determining the presence of a target sequence of nucleotides in a polynucleotide analyte in a sample suspected of containing the polynucleotide analyte. The method comprises combining said sample either wholly or partially sequentially or simultaneously with one or more of (1) means capable of causing the target sequence to be terminated in a 3′-OH group, (2) a single stranded pattern oligodeoxynucleotide template comprised of a sequence complementary to the target sequence, the sequence bonded at its 5′ end to a multiply repeating sequence of at least 12 nucleotides which, when hybridized to a complementary sequence allows cleavage of said complementary sequence to form fragments, (3) deoxynucleoside triphosphates, (4) DNA dependent DNA polymerase and (5) a restriction enzyme for cleaving the complementary sequence when hybridized to the cleavage promoting sequence. The method further comprises incubating the individual components and mixtures formed therefrom under conditions which promote either wholly or partially sequential or simultaneous (a) denaturation of the target sequence when the target sequence is double stranded, (b) hybridization of the target sequence with the template, (c) extension of the target sequence by DNA dependent DNA polymerase to produce a duplex containing the complementary sequence, (d) cleavage of the complementary sequence in the duplex into fragments, (e) melting of the duplex, and f(f) hybridization of the fragments with single stranded pattern polynucleotide, and extension of the fragments by DNA dependent DNA polymerase to produce a duplex containing the complementary sequence and repeating the above steps. Thereafter, the complementary sequence or fragments of the template produced during cleavage of said complementary sequence are detected. The presence thereof indicates the presence of the analyte in said sample.
- Another aspect of the present invention involves a polydeoxynucleotide comprising a single stranded DNA oligomer consisting of from about 3 to 100, preferably 6 to 50, oligonucleotide units and at least one restriction site. Each oligodeoxynucleotide unit consists of an oligodeoxynucleotide template containing at least one restriction site and having from about 8 to 100, preferably 10 to 50 nucleotides. Preferably, the monomer units are identical. The oligodeoxynucleotide can be cyclic or non-cyclic and is preferably cyclic. The DNA oligomer can be bonded at its 3′ end to a single stranded polynucleotide binding sequence consisting of at least about 15 nucleotides. Preferably, the oligomer and any polynucleotide sequence connecting the oligomer and the binding sequence are composed of two or three, preferably three, members selected from the group of nucleotides and deoxynucleotides or a corresponding derivative thereof. Preferably, the nucleotides are selected from three members of the group consiting of A and dA or a derivative thereof, U and dT or a derivative thereof, G and dG or a derivative thereof and C and dC or a derivative thereof. When cyclic, the 5′ end of the DNA oligomer can be connected directly or through a polynucleotide sequence to the 3′ end of the binding sequence to form a ring. The oligonucleotide can preferably contain from about 3 to 100, preferably 6 to 50, template sequences, and the template sequences can preferably each consist of from about 8 to 100, preferably 10 to 50, more preferably 10 to 20, nucleotides. Reporter groups can be bound to the DNA oligomer, preferably, one reporter group per monomer unit. The reporter groups include radioactive molecules, fluorescers, chemiluminescers, small organic groups of molecular weight of from about 17 to 1000 such as biotin, NH₂, OH, SH, fluorescein, etc., and the like.
- Various techniques can be employed for preparing a single stranded pattern polynucleotide in accordance with the present invention. In an approach for preparing an oligomer of a template sequence, the single stranded pattern polynucleotide can be prepared by enzymatic ligation. An appropriate oligonucleotide which is identical to the template or upon ligation with itself forms a template sequence, can be synthesized by standard automated techniques. It is then enzymatically ligated together, for example, by T4 ligase, to produce the single stranded pattern polynucleotide. Oligomers of the desired lenght can then be isolated, for example, by polyacrylamide gel electrophoresis or high performance liquid chromatography (HPLC). Frequently, the 3′ end of the oligomer will be modified to prevent reaction with template dependent DNA polymerase or to append a binding sequence, preferably catalyzed by a ligase. The 3′-end can also be modified by ligation of a dideoxynucleotide or a ribonucleotide followed by oxidation of the ribose with periodate followed by reductive amination of the resulting dialdehyde with borohydride and a bulky amine such as aminodextran.
- In another approach the single stranded polynucleotide can be prepared by recombinant DNA technology. In another approach, the single stranded pattern polynucleotide can be synthesized entirely by standard solid phase automatable methods as, for example, by use of phosphoamidates. In this method the group anchoring the synthetic sequence to the solid support can be released at the last step and can serve to prevent reaction of the 3′ end with DNA polymerase. Alternatively, the single stranded pattern polynucleotide may be left covalently bonded at the 3′ end to a solid support and thus blocked. The solid support can be, for example, a bead, sheet, particle, or the like composed of synthetic or natural material such as, for example, organic polymer, glass, inorganic polymer and the like. This material may be subsequently extented at its 5′ end and increased in the number of its template units by chemical or enzymatic ligation with other oligonucleotides. In a preferred approach the single stranded pattern polynucleotide can be prepared by standard cloning techniques, for example, by use of the cyclic single stranded M13 phage. In this approach the synthetic oligomer terminating in cleaved restriction sites is inserted at the corresponding restriction site into the polylinker region of M13. Where desired, a binding polynucleotide sequence can be similarly inserted. The phage is then cloned and harvested.
- An important consideration in whatever approach is utilized to prepare the single stranded pattern polynucleotide is that the single stranded pattern polynucleotide be free from complementary polynucleotide sequences. The presence of complementary sequences will result in random initiation of chain extension.
- A particularly preferred composition for use in the method of the present invention is a cyclic single stranded pattern polydeoxynucleotide having at least three contiguous, preferably, identical, template sequences of polydeoxynucleotides. Each template sequence contains at least one restriction site. These sequences and any sequence connecting the binding polynucleotide sequence with the template sequence oligomer lack one member of the group of nucleotides comprising adenine (A) and deoxyadenine (dA), guanidine (G) and deoxyguanidine (dG), cytidine (C) and deoxycytidine (dC), and thymidine(T) and deoxythymidine (dT) or a corresponding derivative thereof. The absence of one of the bases together with the use of only the nucleoside triphosphates complementary to the remaining three bases in the deoxynucleotide polymerase catalyzed reactions considerably reduces or eliminates random initiation of chain extension at polynucleotide sequences outside the template sequence oligomer and any sequence connecting it to the binding polynucleotide sequence. Thus, chain extension can occur along the template sequences, but random hybridization at some other point on the cyclic pattern polynucleotide or polynucleotide analyte will continue only for a very short distance until a nucleotide is encountered which is complementary to the nucleotide absence in the deoxynucleoside triphosphate mixture.
- The template sequence in the above cyclic pattern polynucleotide preferably contains from eight to one hundred nucleotides. The cyclic pattern polynucleotide usually contains from about 3 to 50, preferably at least 6 template sequences. A preferred cyclic pattern polynucleotide for use in the present method is a synthetic sequence cloned into M13, φX174, or the like.
- As a matter of convenience, the reagents employed in the present invention can be provided in a kit in packaged combination with predetermined amount s of reagents for use in obtaining multiple copies of a primary polynucleotide sequence or for use in assaying for a polynucleotide analyte in a sample. For example, a kit useful in the present method can comprise in packaged combination with other reagents a composition such as that described above. The kit can further include in the packaged combination nucleoside triphosphates such as deoxynucleoside triphosphates, e.g., deoxyadenosine triphosphate (dATP), deoxyguanosine triphosphate (dGTP), deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP). The kit can further include template-dependent polynucleotide polymerase and also means for cleaving the site specific cleavage sequences or the sequences complementary thereto or both. Where the target polynucleotide sequence is RNA, the kit can further include in packaged combination a single stranded DNA primer. The DNA primer comprises a nucleic acid sequence capable of hybridizing with the RNA and containing a restriction site. The primer is terminated at its 3′ end by a group incapable of reacting in a chain extension in the presence of template-dependent polynucleotide polymerase. Where a restriction enzyme is used for cleaving the cleavable sequences that is different from the restriction enzyme used for providing that the target sequence terminate in a 3′ hydroxyl group, the kit can further include a packaged combination the restriction enzyme for causing the target sequence or complementary sequence to terminate in a 3′ hydroxy group. For assays for the determination of a polynucleotide analyte the kit can include one or more of the above in packaged combination with other reagents for conducting an assay and reagents for detecting DNA fragments as described above.
- The relative amounts of the various reagents in the kits can be varied widely to provide for concentrations of the reagents which substantially optimize the production of, and the rate of production of, multiple copies of the primary polynucleotide sequence. For kits to be used in conducting an assay the reagents can be provided to further substantially optimize the sensitivity of the assay. Under appropriate circumstances one or more of the reagents in the kit can be provided as a dry powder, usually lyophilized, including excipients, which on dissolution will provide for a reagent solution having the appropriate concentrations for performing a method or assay in accordance with the present invention.
- The invention is demonstrated further by the following illustrative examples.
- Polymerase mediated DNA target amplification was demonstrated in an experiment using circular M13 as a single stranded pattern polynucleotide. A 17 base synthetic target DNA polynucleotide was annealed to complementary single stranded pattern polynucleotide containing two non-identical template sequences M13mp19 DNA and elongated with Klenow fragment polymerase and all four deoxynucleoside triphosphates (dNTPs). The restriction endonucleases Eco RI, Bam HI, and Hind III specifically cleaved the elongated double stranded DNA under polymerase reaction conditions. The amount of primary polynucleotide fragments produced could be substantially increased by thermal cycling of the reaction. This cycling was accomplished by boiling the reaction mixture, allowing DNA strand renaturation in the presence of excess pattern polynucleotide template at a lower temperature, and continuing the polymerization/cutting by the addition of fresh enzymes. Primary polynucleotide fragments were observed after gel electrophoresis under denaturing conditions. No fragments were observed in control reactions where target DNA was absent.
- M13mp19 single stranded DNA (Lot No. 63102) and the 17 base DNA (Lot No. 62101) were purchased from Bethesda Research Labs (BRL), Gaithersburg, MD. The 17 base DNA has the
nucleotide sequence 5′GTAAAACGACGGCCAGT 3′. This DNA functioned as a target polynucleotide sequence in the system described here and is referred to herein also as the target polynucleotide. - Klenow fragment DNA-dependent DNA polymerase (Lot No. NM 92818; supplied as an FPLCpure™ 7.2 units/µl solution) was purchased from Pharmicia Inc., Piscataway, NJ. The restriction endonucleases Eco RI (Lot No. 411L1, 10 units/µl), Hind III (Lot No. 51111, 10 units/µl), and Bam HI (Lot No. 461D1, 10 units/µl) were purchased from BRL.
- Klenow polymerase buffer (10X) was 70 mM Tris-HCl (pH = 7.5), 70 mM MgCl₂, and 500 mM NaCl. The four deoxynucleoside triphosphates (dATP, dGTP, dCTP, and dTTP) were purchased as 100 mM solutions from Pharmacia Inc. Water was sterile filtered Milli-Q reagent grade⁺. All chemicals were reagent grade or better. Electrophoresis reagents were purchased from Bio-Rad Inc., Richmond, CA. α-³²P dTTP (3000 Ci/mmol; 10 mCi/ml) was purchased from New England Nuclear Corp., Boston, MA.
- 1.0 µl of 17 base DNA (2 ng/
m 1; 2 ng ≃ 180 fmoles), 20.5 µl of M13mp19 single stranded DNA (10 µg/41 µl; 4 µg ≃ 2.1 pmoles) and 6.0 µl of 10X Klenow polymerase buffer were added to a sterile 1.5 ml Eppendorf tube, mixed by vortex, and spun briefly to recover the volume in the bottom of the tube. The mixture was incubated at 60°C for 5 minutes and then allowed to cool to room temperature (approximately 30 minutes). After cooling, 21.5 µl of α-³²P dTTP, 4.0 µl of dNTPs (0.4 mM each), and 4.0 µl of DTT (01. M) were added to the reaction. A 4.0 µl aliquot was removed from the reaction as a zero time point before the addition of enzymes. In parallel with the target containing reaction described above, an identical control reaction was run substituting 1.0 µl of water for the target polynucleotide sequence. - For the first cycle, 1.0 µl of Klenow polymerase and 1.0 µl of each of the three restriction endonucleases (Eco RI, Hind III, and Bam HI) were added to the reaction. The reactions were incubated at 37°C for 2 minutes and then transferred to a boiling water bath for 5 minutes to effect denaturation of the fragments produced. Previous experiments had shown that under the present conditions primary polynucleotide elongation beyond the three restriction endonuclease sites was complete after 2 minutes. After denaturation, the tubes were placed at 60°C for 10 minutes and then 37°C for 5 minutes. The reactions were spun briefly to recover all the liquid into the bottom of the tube, and then a 4.0 µl aliquot was withdrawn for analysis (cycle #1). Fresh enzymes were added the second polymerization cycle was started. This procedure was repeated for a total of four cycles.
- Aliquots taken after each cycle from both the tubes containing the target polynucleotide and the control were analyzed by 20% polyacrylamide gel electrophoresis under denaturing conditions (8 M urea; 56°C). Radioactively labeled DNA markers were co-electrophoresed to estimate the sizes of the bands observed.
- Table III summarizes the densitometry data obtained from an analysis of the gel autoradiogram. A comparison is also shown in this Table between the values observed for the relative peak intensities and those expected theoretically.
Table III Cycle # Relative amount of 21 mer fragment Relative amount 30 mer fragment Observed* Expected Observed* Expected 1 1 1 1 1 2 2.05 2 1.72 3 3 2.99 3 1.59 6 4 3.88 4 4.45 10 * Normalized to the amount of material observed after the first cycle. - A repeating polydeoxynucleotide of sequence: and an oligodeoxynucleotide of
sequence 5′CGGCCAGTGAATTCGGA 3′ (17 mer) were synthesized by the phosphoramidite method. A portion of the 17 mer (50 ng, 8.9 pmoles) was radioactively labeled at the 5′ end with α-³²P ATP(Lot #2387-299 NEN, 3000 Ci/mmole, 10 m Ci/ml) T4 polynucleotide kinase using standard methods (Maxam, A. and Gilbert, W. (1980) Methods in Enzymology 65, 499) to follow the subsequent enzymatic reactions. The radioactive 17 mer was purified by NENSORB ™ chromatography (DuPont/New England Nuclear) using the protocol provided by the supplier. - The 120 mer (1 µg = 25 pmoles) was incubated with a ten-fold molar excess f(1.4 µg = 250 pmoles) of 17 mer including all of the radioactively labeled 17 mer described above at 60°C for 5 minutes and then slowly cooled over 30 minutes to 37°C in a volume of 20.2 µl in 1.3X Klenow buffer (1X Klenow buffer is 7 mM Tris-HCl (pH 7.5), 7 mM MgCl₂, 50 mM NaCl). To this cooled reaction mix was added 2 µl of a solution of 0.4 mM dATP, dCTP, dGTP, dTTP (final conc. = 32 µM of each dNTPs), 1.8 µl of 0.1 M dithiothreitol (final conc. = 7.2 µM)and 7.2 units of Klenow polymerase (Pharmacia Lot #NM 92818) in a final concentration of 1X Klenow buffer. This reaction was incubated at 37°C for 30 minutes. An additional 7.2 units of Klenow polymerase (1 µl volume) was added and the reaction was continued at 37°C for one hour.
- The reaction products were ethanol precipitated by the addition of 375 µl of 0.3 M Na Acetate (pH 5.4) and 1.1 ml ethanol (-20°C), followed by spinning at 15,000 g's for 30 minutes. The precipitated DNA was then resuspended in 25 µl of H₂O and reprecipitated with 1 ml of 100% ethanol (4°C) and centrifugation as above. The supernatant was removed and the precipitated DNA pellet dried under vacuum.
- The pellet was resuspended in 17 µl of distilled water, and 2 µl of Eco RI restriction enzyme buffer (final concentration = 50 mM Tris (pH 8.0), 10 mM MgCl₂, 100 mM NaCl) and 1 µl (20 unit) Eco RI restriction endonuclease (Bethesda Research Labs, final concentration = 1 unit/µl). The reaction was allowed to proceed for 1 hour at 37°C. 1 µl of this reaction was analyzed by 20% polyacrylamide/8 M urea gel electrophoresis to confirm complete digestion of Eco RI restriction sites. The remainder of the reaction products (19 µl) was purified by NENSORB ™ chromatography and evaporated to dryness.
- Bacteriophage M13mp19 replicative form DNA (Garisch-Perran, C., Vieira, J., and Messing, J. (1985) Gene 33, 103-119) was digested (1.3 µg) with Eco RI restriction enzyme and frozen to inactivate the restriction enzyme. 135 ng of this linearized M13mp19 was added to the total Klenow polymerizatin/Eco RI restriction products above, with 0.5 mM ATP, 1 unit of T4 DNA ligase (Bethesda Research Labs, Lot #51131), 66 mM Tris-HCl (pH 7.6), 6.6 mM MgCl₂, and 10 mM dithiothreitol in a final reaction volume of 20 µl. Reaction was performed at 12°C for 18 hours.
- Ten (10) µl of this reaction mix in five 2µl aliquots was incubated with E. coli JM 101 bacterial cells rendered competent for DNA transformation using standard protocols (Maniatis, et al. "Molecular Cloning," Cold Spring Harbor Laboratory, [1982]). The five transformations were plated on YT media petri dishes and incubated overnight at 37°C (Maniatis, pp. 320-321). These petri plates were screened in duplicate with nitrocellulose filter replicas by standard methods (Benton, W. D. and R. W. Davis (1977) Science f196, 180). The radioactive probe used for screening was the starting 120 mer which was 5′³²P labeled to an approx. specific activity of 2 x 10⁷ cpm/µg.
- Autoradiography of the dried filters showed approximately 100 M13mp19 infected JM 101 colonies which hybridized to the radioactive probe in the five petri plates. Seven of these positive clones were picked at random. These were sequenced by Sanger dideoxy sequencing (Sanger, F., et al. (1980) J. Mol. Biol. 143, 161) and found each to contain a single insertion in the same orientation of the expected Eco RI bracketed repeating polynucleotide sequence. This clone is hereinafter referred to as the "M13mp19 Dra I clone.
- Using the sequence (or a multimer of it) directly adjacent to a target DNA sequence has a number of advantages:
- 1. Only a single restriction endonuclease is needed to generate a number of fragments.
- 2. Six of the fragments are ofthe same sequence and length, resulting in improvement of the amplification.
- 3. Since only three bases are needed for polymerization, background from linear DNAs can be greatly reduced by eliminating dGTP (or dCTP if the complement is cloned into the viral strand) from the reaction.
- 4. A generalized amplification reagent or amplification cassette is possible with this sequence.
- A 23 base long oligodeoxynucleotide primer of
sequence 5′- GTAAAACGACGGCCAGTGAATTC -3′ was hybridized to the M13mp19 Dra I clone in a volume of 50 microliters. The total amount of primer in the hybridization was 0.021 pmoles; the total amount of M13mp19 Dra I clone was 2.1 pmoles. Hybridization was done under temperature and buffer conditions previously described. - Four parallel polymerization reactions were performed at 37°C. The polymerase used was either 14.4 units of Klenow polymerase (Pharmacia, Lot # NM92818) in two separate reaction volumes or 2.75 units T7 polymerase (United States Biochemical Corporation, Lot # 51255) in the two remaining reactions. 40 units of restriction endonuclease Dra I was included in one of the Klenow and one of the T7 polymerizations. Only three deoxynucleoside triphosphates were included in the polymerizations, dATP, dCTP and dTTP, each at final concentration of 32µM.
- Aliquots were taken from the reaction at 0, 2, 4, 6, 10, 20 and 30 minutes. These were mixed with an appropriate volume of 95% formamide and bromophenol blue, xylene cyanol dyes and electrophoresed on 20% denaturing acrylamide gels. Autoradiography of the gels revealed the expected 12 base long oligonucleotide bands plus higher moleculer weight multimers of the 12 mer when both a polymerase and Dra I restriction enzyme were included in the reaction. In the presence of polymerase, but without the addition of Dra I, no radioactive product is evident on the autoradiogram. Table IV lists the integrated areas for each of the fragment bands obtained with T7 polymerase elongation in the presence of Dra I. Densitometry was performed with a ZEINEH soft laser densitometer model SL-504-XL (Biomed Instruments Inc., Fullerton, CA). No bands were observed within the gel in the absence of Dra I restriction endonuclease.
Table IV Integrated areas obtained from laser densitometry of the gel autoradiogram bands Incubation Time(min) Fragment Sizes 12 24 36 48 0 0 0 0 0 2 0 0 0 0 4 56 10 0 0 6 159 74 29 0 10 532 131 43 6 20 871 127 34 6 30 664 800 360 213 -
Oligodeoxyribonucleotide sequences oligomers oligomer 2 from its 3′terminus using oligmer 1 sequence as template, thus synthesizing a double stranded DNA molecule.Oligomers
5′TTTTTTTTTCTTCTT3′ (a)
3′AAAAAAAAAGAAGAA5′ (B) - These 15 mer repeats can be melted apart by temperatures exceeding 50°C and, in the presence of molar
excess oligomer 1, the 15 mer single stranded oligomer (B) will hybridize tooligomer 1 upon cooling of the reaction to approximately 37°C. Hence more "primed" template has been introduced into the reaction by the successive use of DNA polymerization, Mbo II restriction digestion and a heating/cooling (melting/annealing) step. Repetition of this protocol will lead to continued DNA synthesis until precursor dNTP's are exhausted or substrate single strandedoligomer 1 becomes limiting. The use of a heat stable DNA polymerase from the thermophili organism Thermus aquaticus allows retention of DNA polymerase activity through successive heat/cool cycles and thereby eliminates the need for repeated additions of fresh enzyme. - Amplification
experiments using oligomers - Taq DNA polymerase was purchased from Perkin-Elmer Cetus and Mbo II restriction enzyme from Pharmacia.
- A Table of TCA precipitations from aliquots withdrawn from the amplification experiments at various timepoints is shown (TABLE 1). Incorporation of ³²P from precursor α-³²dATP into polynucleotide was followed by standard TCA protocols (Maniotis, pg. 473). This experiment was performed in the presence and absence of 5 fmoles of
oligomer 2 and with 1 pmole ofoligomer 1. - It can be seen from the Table that the rate of ³²P incorporation into polynucleotide is much faster in the presence of 5
fmoles primer oligomer 2 compared to an absence of primer. The presence of primer is most dramatically assayed in the period between 2 and 4 hrs. of incubation. Hence primer dependent and primer independent DNA polymerization is noticeably separated by about two hours under these conditions.TABLE 1 TCA Precipitable Polynucleotide in DNA Amplification Reactions (³²P cpm) Hrs of Incubation +Mbo II Enzyme Primer Absent +Mbo II Enzyme +5 fmole Primer 2 0 0 4 1230 8360 6 10470 24810 8 21300 30900 10 22840 32570 - The polynucleotide sequence shown below (which may be prepared by standard techniques) was cloned into BamHI and EcoRI restriction enzyme linearized M13mp18 bacteriophage RF (commercially awaitable, for example from Bethesda) by standard methods. Bacteriophage containing the single stranded circular genome with the cloned insert were isolated from the infected, plaque purified, E. coli JM 101 host cells. DNA isolated from these bacteriophage proved to have the expected sequence and orientation of the DNA insert, namely the "TTCTTC(T)₉" repeat orientation. This bacteriophage DNA is not a subtrate for Mbo II restriction enzyme (data now shown).
- An oligodeoxynucleotide shown below:
Oligomer 3
5′GGTCGACTCTAGAGGATCCCCGGG 3′
was synthesized by standard phosphoramidite chemistries. This DNA will act as a "primer" and hybridize across a portion of the M13mp18 DNA sequence flanking sequence as well as a short region of the insert. - Amplification reactions using this M13mp18 "Mbo II repeat" clone in the presence or absence of
oligomer 3 primer were performed essentially as described in Example 4. Table 2 shows the TCA precipitation data from a representative experiment. As can be seen from the Table, no significant α-³²P dATP incorporation into polynucleotide can be seen in the absence of Mbo II enzyme addition. In the presence of primer and Mbo II, ³²P incorporation is accelerated significantly compared to when no primer is added. Between 4.2 hours and 6.5 hours these two reactions are easily distinguishable in their ability to detect the presence of 10 femptomoles (fmoles) or primer.TABLE 2 TCA Precipitable Polynucleotide in DNA Amplification Reactions (³²P cpm) Hrs. of Incubation Absent Mbo II Enzyme Absent primer Absent Mbo II Enzyme +10 fmoles primer +Mbo II Enzyme Absent primer +Mbo II Enzyme +10 fmoles primer 0.5 0 320 1400 290 2.6 270 570 1650 4110 4.2 760 520 1600 24050 5.0 950 990 2060 61000 6.0 1100 1330 2400 68870 6.5 1200 900 1970 74620 - Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
Claims (19)
(a) forming in the presence of nucleoside triphosphates and template-dependent polynucleotide polymerase an extension of a primary polynucleotide sequence hybridized with at template sequence of a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more cleavable sites,
(b) cleaving into fragments said extension at cleavable sites in the presence of means for specifically cleaving said cleavable sites when said extension is hybridized with said template sequence,
(c) dissociating said fragments, comprising a primary polynucleotide sequence,
(d) hybridizing said fragments with said single stranded pattern polynucleotide, and
repeating steps (a)-(d) above wherein steps (a)-(d) are conducted simultaneously or wholly or partially sequentially.
(a) forming in the presence of nucleoside triphosphates and template-dependent polynucleotide polymerase an extension of a primary polynucleotide sequence hybridized with a template sequence of a single stranded pattern polynucleotide comprising two or more template sequences each containing one or more site specific cleavage sequences,
(b) cleaving into fragments said extension at cleavable polynucleotide sequences in the presence of means for specifically cleaving said cleavable polynucleotide sequences when said extension is hybridized with said site specific cleavage sequences,
(c) dissociating said fragments, comprising a primary polynucleotide sequence,
(d) hybridizing said fragments with said single stranded pattern polynucleotide, and
repeating steps (a)-(d) above wherein steps (a)-(d) are conducted simultaneously or wholly or partially sequentially.
combining in an aqueous medium said sample, a single stranded DNA primer comprising a deoxynucleic acid sequence containing a restriction site and capable of hybridizing with said RNA sequence, and a restriction enzyme capable of cleaving said primer at said restriction site when said primer is hybridized with said RNA sequence, and
incubating said medium for a time sufficient to permit cleaving to occur.
combining either simultaneously or wholly or partially sequentially (1) said sample, (2) means for causing said polynucleotide analyte to be terminated in a 3′-OH group when said analyte is not terminated in a 3′-OH group, (3) a single stranded pattern polynucleotide comprising a binding polynucleotide sequence hybridizable with said polynucleotide analyte and connected to the 3′ end of a strand of two or more template sequences connected in tandem and containing site specific cleavage sequences, (4) nucleoside triphosphates, (5) template-dependent polynucleotide polymerase, and (6) means for specifically cleaving cleavable polynucleotide sequences complementary to said site specific cleavage sequences when said cleavable polynucleotide sequences are hybridized with said site specific cleavage sequences and
incubating said combination under conditions for either simultaneously or wholly or partially sequentially (a) causing said polynucleotide analyte to be terminated in a 3′-OH group when said analyte is not terminated in a 3′-OH group, (b) hybridizing said polynucleotide analyte with said single stranded pattern polynucleotide, (c) forming an extension of said polynucleotide analyte comprising a sequence complementary to said template sequence and to said site specific cleavage sequences, (d) cleaving said extension into fragments at said cleavable polynucleotide sequences, (e) dissociating said fragments, (f) hybridizing said dissociated fragments with single stranded pattern polynucleotide, and (g) forming an extension of said hybridized fragments along said pattern polynucleotide, and repeating steps (d)-(g), and
determining the presence of said fragments, or fragments complementary thereto, the presence thereof indicating the presence of said polynucleotide analyte in said sample.
combining either wholly or partially sequentially or simultaneously (1) said polynucleotide sample containing said target sequence, (2) means to cause said target sequence to terminate in a free 3′-OH group when said target sequence does not already terminate in a free 3′-OH group, (3) a single stranded pattern polynucleotide comprising a binding polynucleotide sequence complementary to substantially all of said target sequence, joined at its 5′ end to two or more template sequences each containing site specific cleavage sequence, (4) nucleoside triphophates, (5) template-dependent polynucleotide polymerase, and (6) means for cleaving a sequence complementary to said site specific cleavage sequences when hybridized with said site specific cleavage sequence,
said combining being carried out under conditions which promote either wholly or partially sequentially or simultaneously (a) denaturation of said target sequence when said target sequence is double stranded, (b) hybridization of said target sequence with said binding polynucleotide sequence, (c) extension of said target sequence by template dependent polymerization to produce a duplex, (d) cleavage of said extension in said duplex into fragments, (e) reversible denaturation of said fragments, (f) hybridization of said fragments with single stranded pattern polynucleotide, and (g) extension of said hybridized fragments by template dependent polymerization to produce a duplex, and
repeating steps (d)-(g).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT88306717T ATE96180T1 (en) | 1987-07-23 | 1988-07-21 | AMPLIFICATION PROCEDURE FOR THE DETECTION OF POLYNUCLEOTIDES. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76807 | 1987-07-23 | ||
US07/076,807 US4994368A (en) | 1987-07-23 | 1987-07-23 | Amplification method for polynucleotide assays |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0300796A2 true EP0300796A2 (en) | 1989-01-25 |
EP0300796A3 EP0300796A3 (en) | 1989-07-19 |
EP0300796B1 EP0300796B1 (en) | 1993-10-20 |
Family
ID=22134303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88306717A Expired - Lifetime EP0300796B1 (en) | 1987-07-23 | 1988-07-21 | Amplification method for polynucleotide assays |
Country Status (8)
Country | Link |
---|---|
US (1) | US4994368A (en) |
EP (1) | EP0300796B1 (en) |
JP (1) | JP2788034B2 (en) |
AT (1) | ATE96180T1 (en) |
AU (1) | AU622863B2 (en) |
CA (1) | CA1301672C (en) |
DE (1) | DE3885027T2 (en) |
ES (1) | ES2045127T3 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0332435A2 (en) * | 1988-03-10 | 1989-09-13 | Zeneca Limited | Method of detecting nucleotide sequences |
EP0357336A2 (en) * | 1988-08-25 | 1990-03-07 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
FR2648152A1 (en) * | 1989-06-12 | 1990-12-14 | Oris Ind Cie | Process for the detection and/or identification of nucleic acids by amplification and hybridisation in solution, and its applications |
EP0408295A2 (en) * | 1989-07-11 | 1991-01-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
EP0461496A1 (en) * | 1990-06-08 | 1991-12-18 | BEHRINGWERKE Aktiengesellschaft | Method for the quantitative determination of DNA sequences |
EP0530526A1 (en) * | 1991-08-13 | 1993-03-10 | Bayer Corporation | Novel amplification method for polynucleotide assays |
EP0587298A2 (en) * | 1992-08-04 | 1994-03-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification method |
US5399491A (en) * | 1989-07-11 | 1995-03-21 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
EP0646596A1 (en) * | 1993-09-13 | 1995-04-05 | Bayer Ag | Nucleic acid binding oligomers having C-branches for therapy and diagnosis |
EP0646595A1 (en) * | 1993-09-13 | 1995-04-05 | Bayer Ag | Nucleic acid binding oligomers having C-branches for therapy and diagnosis |
EP0705905A2 (en) * | 1994-07-16 | 1996-04-10 | Roche Diagnostics GmbH | Method for the sensitive detection of nucleic acids |
US5554516A (en) * | 1992-05-06 | 1996-09-10 | Gen-Probe Incorporated | Nucleic acid sequence amplification method, composition and kit |
US5639599A (en) * | 1992-06-08 | 1997-06-17 | Gen-Probe Incorporated | Amplification of nucleic acids from mononuclear cells using iron complexing and other agents |
US5726015A (en) * | 1991-05-15 | 1998-03-10 | Vanderbilt University | Method to determine metastatic potential of tumor cells |
EP0832292A1 (en) * | 1995-06-07 | 1998-04-01 | Merck & Co., Inc. | Dna polymerase extension assay for influenza virus endonuclease |
EP0833945A1 (en) * | 1995-06-07 | 1998-04-08 | Merck & Co., Inc. | Dna polymerase extension assay |
WO1999024608A1 (en) * | 1997-11-10 | 1999-05-20 | Technion Research And Development Foundation Ltd. | Method for labeling polynucleotides |
US5908744A (en) * | 1989-07-11 | 1999-06-01 | Gen-Probe Incorporated | Detecting Mycobacterium tuberculosis by nucleic acid sequence amplification |
US6087133A (en) * | 1994-03-16 | 2000-07-11 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
US6100028A (en) * | 1996-06-03 | 2000-08-08 | Merck & Co., Inc. | DNA polymerase extension assay |
US6589734B1 (en) | 1989-07-11 | 2003-07-08 | Gen-Probe Incorporated | Detection of HIV |
US7009041B1 (en) | 1989-07-11 | 2006-03-07 | Gen-Probe Incorporated | Oligonucleotides for nucleic acid amplification and for the detection of Mycobacterium tuberculosis |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
EP2242858A2 (en) * | 2008-01-08 | 2010-10-27 | Zygem Corporation Limited | Isothermal detection methods and uses thereof |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US5622820A (en) * | 1988-03-10 | 1997-04-22 | City Of Hope | Method for amplification and detection of RNA and DNA sequences |
GB8818020D0 (en) * | 1988-07-28 | 1988-09-01 | Ici Plc | Method for amplification of nucleotide sequences |
DE69032778T2 (en) * | 1989-07-18 | 1999-07-29 | Shimadzu Corp., Kyoto | Process for examining food poisoning caused by microorganisms and reagent therefor |
DK0490951T3 (en) * | 1989-09-06 | 1996-08-26 | Pasteur Institut | Nucleic acid fragments from a genome of a suitable mycobacteria, their use in the diagnosis of mycobacterial infections as well as plasmids containing these fragments |
AU7233691A (en) * | 1990-01-16 | 1991-08-05 | Collaborative Research Inc. | Dna sequences from specific human genomic loci useful for identification of individuals |
AU650040B2 (en) * | 1990-07-24 | 1994-06-09 | Uab Research Foundation, The | Methods of use of bovine respiratory syncytial virus recombinant DNA, proteins vaccines, antibodies, and transformed cells |
US6730305B1 (en) | 2000-05-08 | 2004-05-04 | The Uab Research Foundation | Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
US5645987A (en) * | 1990-09-21 | 1997-07-08 | Amgen Inc. | Enzymatic synthesis of oligonucleotides |
DK0502180T3 (en) * | 1990-09-21 | 1997-09-22 | Amgen Inc | Enzymatic synthesis of oligonucleotides |
US5525462A (en) * | 1991-05-02 | 1996-06-11 | Toyo Boseki Kabushiki Kaisha | Nucleic acid sequence amplification method, detection method, and reagent kit therefor |
US5846717A (en) * | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US5994069A (en) * | 1996-01-24 | 1999-11-30 | Third Wave Technologies, Inc. | Detection of nucleic acids by multiple sequential invasive cleavages |
US5612199A (en) * | 1991-10-11 | 1997-03-18 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
USH1985H1 (en) | 1992-01-09 | 2001-08-07 | The United States Of America As Represented By The Secretary Of The Navy | Method for detecting biological toxins |
US6372424B1 (en) * | 1995-08-30 | 2002-04-16 | Third Wave Technologies, Inc | Rapid detection and identification of pathogens |
US6673616B1 (en) * | 1992-12-07 | 2004-01-06 | Third Wave Technologies, Inc. | Methods and compositions for characterizing nucleic acids |
US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
US5824787A (en) * | 1993-12-03 | 1998-10-20 | Gensura Laboratories, Inc. | Polynucleotide sizing reagent |
US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5597697A (en) * | 1994-09-30 | 1997-01-28 | Diamond; Paul | Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases |
DE4441626A1 (en) * | 1994-11-23 | 1996-05-30 | Boehringer Mannheim Gmbh | Method for the particularly sensitive detection of nucleic acids |
US5668263A (en) * | 1994-12-16 | 1997-09-16 | Smithkline Beecham Corporation | Conserved yeast nucleic acid sequences |
US5877280A (en) * | 1995-06-06 | 1999-03-02 | The Mount Sinai School Of Medicine Of The City University Of New York | Thermostable muts proteins |
US5932450A (en) * | 1995-06-07 | 1999-08-03 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using digestible templates |
US5916777A (en) * | 1995-06-07 | 1999-06-29 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using 3'-ribonucleotide primers |
US5739311A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6482590B1 (en) | 1996-12-20 | 2002-11-19 | Aventis Behring Gmbh | Method for polynucleotide amplification |
US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US6136568A (en) * | 1997-09-15 | 2000-10-24 | Hiatt; Andrew C. | De novo polynucleotide synthesis using rolling templates |
DK1036198T3 (en) | 1997-12-08 | 2013-01-02 | California Inst Of Techn | Method for Preparation of Polynucleotide and Polypeptide Sequences |
US7875440B2 (en) | 1998-05-01 | 2011-01-25 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US6780591B2 (en) * | 1998-05-01 | 2004-08-24 | Arizona Board Of Regents | Method of determining the nucleotide sequence of oligonucleotides and DNA molecules |
US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
GB9822777D0 (en) | 1998-10-20 | 1998-12-16 | Tepnel Medical Ltd | Template chain reaction |
US6818395B1 (en) * | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US7501245B2 (en) * | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
AU2001274635A1 (en) * | 2000-11-10 | 2002-05-21 | Amicogen, Inc. | Method for generating recombinant dna library using unidirectional single-stranded dna fragments |
US6958213B2 (en) * | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) * | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
US7582423B2 (en) * | 2001-02-02 | 2009-09-01 | Novici Biotech Llc | Population of polynucleotide sequence variants |
JP4689940B2 (en) * | 2001-02-02 | 2011-06-01 | ノビシ バイオテック,リミティド ライアビリティ カンパニー | Method for increasing heteroduplex complementarity |
US20050153283A1 (en) * | 2002-08-08 | 2005-07-14 | Padgett Hal S. | Method of increasing complementarity in a heteroduplex |
US7838219B2 (en) * | 2001-02-02 | 2010-11-23 | Novici Biotech Llc | Method of increasing complementarity in a heteroduplex |
US20040142433A1 (en) * | 2001-02-02 | 2004-07-22 | Padgett Hal S. | Polynucleotide sequence variants |
US7297518B2 (en) | 2001-03-12 | 2007-11-20 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension |
US20050106587A1 (en) * | 2001-12-21 | 2005-05-19 | Micronas Gmbh | Method for determining of nucleic acid analytes |
US20030157495A1 (en) * | 2002-02-01 | 2003-08-21 | Padgett Hal S. | Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof |
US7078211B2 (en) * | 2002-02-01 | 2006-07-18 | Large Scale Biology Corporation | Nucleic acid molecules encoding endonucleases and methods of use thereof |
DK1504098T4 (en) * | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Process for molecular evolution in vitro of protein function |
US20050170367A1 (en) * | 2003-06-10 | 2005-08-04 | Quake Stephen R. | Fluorescently labeled nucleoside triphosphates and analogs thereof for sequencing nucleic acids |
US7169560B2 (en) * | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
WO2005054441A2 (en) * | 2003-12-01 | 2005-06-16 | California Institute Of Technology | Device for immobilizing chemical and biomedical species and methods of using same |
DE602005020421D1 (en) | 2004-02-19 | 2010-05-20 | Helicos Biosciences Corp | METHOD FOR THE ANALYSIS OF POLYNUCLEOTIDE SEQUENCES |
US20060046258A1 (en) * | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
US20050239085A1 (en) * | 2004-04-23 | 2005-10-27 | Buzby Philip R | Methods for nucleic acid sequence determination |
ATE507305T1 (en) * | 2004-05-25 | 2011-05-15 | Helicos Biosciences Corp | METHOD FOR NUCLEIC ACID IMMOBILIZATION |
US20070117104A1 (en) * | 2005-11-22 | 2007-05-24 | Buzby Philip R | Nucleotide analogs |
US7476734B2 (en) * | 2005-12-06 | 2009-01-13 | Helicos Biosciences Corporation | Nucleotide analogs |
US20070117103A1 (en) * | 2005-11-22 | 2007-05-24 | Buzby Philip R | Nucleotide analogs |
US20060024678A1 (en) * | 2004-07-28 | 2006-02-02 | Helicos Biosciences Corporation | Use of single-stranded nucleic acid binding proteins in sequencing |
US20060118754A1 (en) * | 2004-12-08 | 2006-06-08 | Lapen Daniel C | Stabilizing a polyelectrolyte multilayer |
US7220549B2 (en) * | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
US20060172328A1 (en) * | 2005-01-05 | 2006-08-03 | Buzby Philip R | Methods and compositions for correcting misincorporation in a nucleic acid synthesis reaction |
US7482120B2 (en) * | 2005-01-28 | 2009-01-27 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
US20060263790A1 (en) * | 2005-05-20 | 2006-11-23 | Timothy Harris | Methods for improving fidelity in a nucleic acid synthesis reaction |
US7666593B2 (en) | 2005-08-26 | 2010-02-23 | Helicos Biosciences Corporation | Single molecule sequencing of captured nucleic acids |
GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
US20070117102A1 (en) * | 2005-11-22 | 2007-05-24 | Buzby Philip R | Nucleotide analogs |
US20070128610A1 (en) * | 2005-12-02 | 2007-06-07 | Buzby Philip R | Sample preparation method and apparatus for nucleic acid sequencing |
US20090305248A1 (en) * | 2005-12-15 | 2009-12-10 | Lander Eric G | Methods for increasing accuracy of nucleic acid sequencing |
WO2016058171A1 (en) * | 2014-10-17 | 2016-04-21 | Shanghai Sidansai Biotechnology Co.,Ltd | Method for directional cloning |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US4423153A (en) | 1981-12-03 | 1983-12-27 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection and determination of cellular DNA |
US4480040A (en) | 1981-12-03 | 1984-10-30 | The United States Of America As Represented By The Secretary Of Agriculture | Sensitive and rapid diagnosis of viroid diseases and viruses |
US4486539A (en) | 1981-10-16 | 1984-12-04 | Orioon Corporation Ltd. | Detection of microbial nucleic acids by a one-step sandwich hybridization test |
US4490472A (en) | 1982-06-17 | 1984-12-25 | Imreg, Inc. | Sensitive tests for malignancies based on DNA detection |
EP0164054A1 (en) | 1984-05-29 | 1985-12-11 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
BE904402A (en) | 1986-03-12 | 1986-09-12 | Univ Libre De Bruxelles Iribhn | Mould for making DNA detection probes - comprising linear mono:strand DNA vector contg. complementary insert and priming sequence, immobilised on a carrier |
EP0194545A2 (en) | 1985-03-15 | 1986-09-17 | Molecular Diagnostics, Inc. | Labelling of oligonucleotides |
EP0200362A2 (en) | 1985-03-28 | 1986-11-05 | F. Hoffmann-La Roche Ag | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0201184A2 (en) | 1985-03-28 | 1986-11-12 | F. Hoffmann-La Roche Ag | Process for amplifying nucleic acid sequences |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4663283A (en) | 1980-03-24 | 1987-05-05 | Genentech, Inc. | Method of altering double-stranded DNA |
EP0224995A1 (en) | 1985-09-06 | 1987-06-10 | Syntex (U.S.A.) Inc. | Homogeneous assay for specific polynucleotides and kit for performing same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6091999A (en) * | 1983-10-25 | 1985-05-23 | Fujirebio Inc | Measurement of polynucleotide |
US4734363A (en) * | 1984-11-27 | 1988-03-29 | Molecular Diagnostics, Inc. | Large scale production of DNA probes |
US4808525A (en) * | 1985-01-31 | 1989-02-28 | University Of Georgia Research Center | Site specific cleavage of DNA |
AU606043B2 (en) * | 1985-03-28 | 1991-01-31 | F. Hoffmann-La Roche Ag | Detection of viruses by amplification and hybridization |
US4746604A (en) * | 1985-05-24 | 1988-05-24 | Enzo Biochem, Inc. | Specific binding assays utilizing a viable cell as a label |
US4876187A (en) * | 1985-12-05 | 1989-10-24 | Meiogenics, Inc. | Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
-
1987
- 1987-07-23 US US07/076,807 patent/US4994368A/en not_active Expired - Lifetime
-
1988
- 1988-07-21 CA CA000572634A patent/CA1301672C/en not_active Expired - Lifetime
- 1988-07-21 DE DE88306717T patent/DE3885027T2/en not_active Expired - Fee Related
- 1988-07-21 JP JP63182780A patent/JP2788034B2/en not_active Expired - Fee Related
- 1988-07-21 AU AU19285/88A patent/AU622863B2/en not_active Ceased
- 1988-07-21 ES ES88306717T patent/ES2045127T3/en not_active Expired - Lifetime
- 1988-07-21 EP EP88306717A patent/EP0300796B1/en not_active Expired - Lifetime
- 1988-07-21 AT AT88306717T patent/ATE96180T1/en active
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663283A (en) | 1980-03-24 | 1987-05-05 | Genentech, Inc. | Method of altering double-stranded DNA |
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US4358535B1 (en) | 1980-12-08 | 1986-05-13 | ||
US4486539A (en) | 1981-10-16 | 1984-12-04 | Orioon Corporation Ltd. | Detection of microbial nucleic acids by a one-step sandwich hybridization test |
US4480040A (en) | 1981-12-03 | 1984-10-30 | The United States Of America As Represented By The Secretary Of Agriculture | Sensitive and rapid diagnosis of viroid diseases and viruses |
US4423153A (en) | 1981-12-03 | 1983-12-27 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection and determination of cellular DNA |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4490472A (en) | 1982-06-17 | 1984-12-25 | Imreg, Inc. | Sensitive tests for malignancies based on DNA detection |
EP0164054A1 (en) | 1984-05-29 | 1985-12-11 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
EP0194545A2 (en) | 1985-03-15 | 1986-09-17 | Molecular Diagnostics, Inc. | Labelling of oligonucleotides |
EP0200362A2 (en) | 1985-03-28 | 1986-11-05 | F. Hoffmann-La Roche Ag | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0201184A2 (en) | 1985-03-28 | 1986-11-12 | F. Hoffmann-La Roche Ag | Process for amplifying nucleic acid sequences |
EP0224995A1 (en) | 1985-09-06 | 1987-06-10 | Syntex (U.S.A.) Inc. | Homogeneous assay for specific polynucleotides and kit for performing same |
BE904402A (en) | 1986-03-12 | 1986-09-12 | Univ Libre De Bruxelles Iribhn | Mould for making DNA detection probes - comprising linear mono:strand DNA vector contg. complementary insert and priming sequence, immobilised on a carrier |
Non-Patent Citations (19)
Title |
---|
"Synthesis and Applications of DNA and RNA", 1987, ACADEMIC PRESS |
ATKINSON ET AL., BIOCHEM., vol. 8, 1969, pages 4897 - 4904 |
BEAUCAGE ET AL., TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1862 |
BENTON, W. D.; R. W. DAVIS, SCIENCE, vol. 196, 1977, pages 180 |
BRIGATI ET AL., VIROLOGY, vol. 126, 1983, pages 32 - 50 |
GARISCH-PERRAN, C.; VIEIRA, J.; MESSING, J., GENE, vol. 33, 1985, pages 103 - 119 |
KASSLER; HÖLTKE, GENE, vol. 47, 1986, pages 1 - 153 |
KRYNETSKAYA ET AL., NUCLEOSIDES AND NUCLEOTIDES, vol. 5, no. 1, 1986, pages 33 - 43 |
LANGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 6633 - 6637 |
MANIATIS ET AL.: "Molecular Cloning", 1982, COLD SPRING HARBOR LABORATORY |
MAXAM, A.; GILBERT, W., METHODS IN ENZYMOLOGY, vol. 65, 1980, pages 499 |
MOLLOY; SYMMS, NUCLEIC ACIDS RES., vol. 8, 1980, pages 2939 - 2946 |
NARANG ET AL., METH. ENZYMOL, vol. 68, 1979, pages 90 |
NELSON; MCCLELLAND, NUCLEIC ACIDS RES., vol. 15, 1987, pages R2L9 - R230 |
PETER DERVAN, SCIENCE, vol. 232, 1986, pages 464 - 471 |
REINES ET AL., NUCLEIC ACIDS RESEARCH, vol. 1, 1974, pages 767 - 786 |
ROBERTS, NUCLEIC ACIDS RES., vol. 15, 1987, pages R189 - R2L7 |
SAIKI ET AL., SCIENCE, vol. 230, 1986, pages 1350 - 1354 |
SANGER, F. ET AL., J. MOL. BIOL., vol. 143, 1980, pages 161 |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0332435A2 (en) * | 1988-03-10 | 1989-09-13 | Zeneca Limited | Method of detecting nucleotide sequences |
EP0332435A3 (en) * | 1988-03-10 | 1990-06-27 | Imperial Chemical Industries Plc | Method of detecting nucleotide sequences |
US5595890A (en) * | 1988-03-10 | 1997-01-21 | Zeneca Limited | Method of detecting nucleotide sequences |
EP0357336A2 (en) * | 1988-08-25 | 1990-03-07 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
EP0357336A3 (en) * | 1988-08-25 | 1991-02-27 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
FR2648152A1 (en) * | 1989-06-12 | 1990-12-14 | Oris Ind Cie | Process for the detection and/or identification of nucleic acids by amplification and hybridisation in solution, and its applications |
EP0408295A2 (en) * | 1989-07-11 | 1991-01-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
US5908744A (en) * | 1989-07-11 | 1999-06-01 | Gen-Probe Incorporated | Detecting Mycobacterium tuberculosis by nucleic acid sequence amplification |
US5824518A (en) * | 1989-07-11 | 1998-10-20 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
US5399491A (en) * | 1989-07-11 | 1995-03-21 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
EP0408295A3 (en) * | 1989-07-11 | 1991-08-28 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
US7083922B2 (en) | 1989-07-11 | 2006-08-01 | Gen-Probe Incorporated | Detection of HIV |
US5888779A (en) * | 1989-07-11 | 1999-03-30 | Gen-Probe Incorporated | Kits for nucleic acid sequence amplification methods |
US5480784A (en) * | 1989-07-11 | 1996-01-02 | Gen-Probe Incorporated | Nucleic acid sequence amplification methods |
US7009041B1 (en) | 1989-07-11 | 2006-03-07 | Gen-Probe Incorporated | Oligonucleotides for nucleic acid amplification and for the detection of Mycobacterium tuberculosis |
US6589734B1 (en) | 1989-07-11 | 2003-07-08 | Gen-Probe Incorporated | Detection of HIV |
EP0461496A1 (en) * | 1990-06-08 | 1991-12-18 | BEHRINGWERKE Aktiengesellschaft | Method for the quantitative determination of DNA sequences |
US6337182B1 (en) | 1990-06-08 | 2002-01-08 | Dade Behring Marburg Gmbh | Method for the quantitative determination of DNA sequences |
US5726015A (en) * | 1991-05-15 | 1998-03-10 | Vanderbilt University | Method to determine metastatic potential of tumor cells |
US5294534A (en) * | 1991-08-13 | 1994-03-15 | Miles, Inc. | Amplification method for polynucleotide assays |
EP0530526A1 (en) * | 1991-08-13 | 1993-03-10 | Bayer Corporation | Novel amplification method for polynucleotide assays |
US5554516A (en) * | 1992-05-06 | 1996-09-10 | Gen-Probe Incorporated | Nucleic acid sequence amplification method, composition and kit |
US5888729A (en) * | 1992-05-06 | 1999-03-30 | Gen-Probe Incorporated | Oligonucleotide probes and methods for detecting Streptococcus pneumoniae |
US5639599A (en) * | 1992-06-08 | 1997-06-17 | Gen-Probe Incorporated | Amplification of nucleic acids from mononuclear cells using iron complexing and other agents |
EP0587298A3 (en) * | 1992-08-04 | 1995-08-30 | Gen Probe Inc | Nucleic acid sequence amplification method |
EP0587298A2 (en) * | 1992-08-04 | 1994-03-16 | Gen-Probe Incorporated | Nucleic acid sequence amplification method |
EP0978570A3 (en) * | 1992-08-04 | 2000-04-12 | Gen-Probe Incorporated | Detecting mycobacterium tuberculosis by nucleic acid sequence amplification |
EP0978570A2 (en) * | 1992-08-04 | 2000-02-09 | Gen-Probe Incorporated | Detecting mycobacterium tuberculosis by nucleic acid sequence amplification |
EP0646596A1 (en) * | 1993-09-13 | 1995-04-05 | Bayer Ag | Nucleic acid binding oligomers having C-branches for therapy and diagnosis |
US5849893A (en) * | 1993-09-13 | 1998-12-15 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics |
EP0646595A1 (en) * | 1993-09-13 | 1995-04-05 | Bayer Ag | Nucleic acid binding oligomers having C-branches for therapy and diagnosis |
US5623049A (en) * | 1993-09-13 | 1997-04-22 | Bayer Aktiengesellschaft | Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics |
US6214587B1 (en) | 1994-03-16 | 2001-04-10 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
USRE39007E1 (en) * | 1994-03-16 | 2006-03-07 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
US6087133A (en) * | 1994-03-16 | 2000-07-11 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
USRE38960E1 (en) * | 1994-03-16 | 2006-01-31 | Gen-Probe Incorporated | Isothermal strand displacement nucleic acid amplification |
EP0705905A3 (en) * | 1994-07-16 | 1999-03-03 | Roche Diagnostics GmbH | Method for the sensitive detection of nucleic acids |
EP0705905A2 (en) * | 1994-07-16 | 1996-04-10 | Roche Diagnostics GmbH | Method for the sensitive detection of nucleic acids |
EP0832292A4 (en) * | 1995-06-07 | 1999-05-26 | Merck & Co Inc | Dna polymerase extension assay for influenza virus endonuclease |
EP0832292A1 (en) * | 1995-06-07 | 1998-04-01 | Merck & Co., Inc. | Dna polymerase extension assay for influenza virus endonuclease |
EP0833945A4 (en) * | 1995-06-07 | 1999-05-19 | Merck & Co Inc | Dna polymerase extension assay |
EP0833945A1 (en) * | 1995-06-07 | 1998-04-08 | Merck & Co., Inc. | Dna polymerase extension assay |
US6100028A (en) * | 1996-06-03 | 2000-08-08 | Merck & Co., Inc. | DNA polymerase extension assay |
WO1999024608A1 (en) * | 1997-11-10 | 1999-05-20 | Technion Research And Development Foundation Ltd. | Method for labeling polynucleotides |
US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
EP2242858A2 (en) * | 2008-01-08 | 2010-10-27 | Zygem Corporation Limited | Isothermal detection methods and uses thereof |
EP2242858A4 (en) * | 2008-01-08 | 2011-01-26 | Zygem Corp Ltd | Isothermal detection methods and uses thereof |
CN101970677A (en) * | 2008-01-08 | 2011-02-09 | 赛进有限公司 | Isothermal detection methods and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
DE3885027T2 (en) | 1994-02-10 |
JPS6460390A (en) | 1989-03-07 |
US4994368A (en) | 1991-02-19 |
JP2788034B2 (en) | 1998-08-20 |
ES2045127T3 (en) | 1994-01-16 |
EP0300796A3 (en) | 1989-07-19 |
DE3885027D1 (en) | 1993-11-25 |
AU1928588A (en) | 1989-01-27 |
EP0300796B1 (en) | 1993-10-20 |
ATE96180T1 (en) | 1993-11-15 |
AU622863B2 (en) | 1992-04-30 |
CA1301672C (en) | 1992-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0300796B1 (en) | Amplification method for polynucleotide assays | |
US5397698A (en) | Amplification method for polynucleotide detection assays | |
EP0652973B1 (en) | Method for introducing defined sequences at the 3' end of polynucleotides | |
EP0549107B1 (en) | Method for producing a polynucleotide for use in single primer amplification and phosphorothioate-containing oligonucleotides as primers in nucleic acid amplification | |
EP0379369B1 (en) | Nucleic acid amplification using single primer | |
EP0469755B1 (en) | Method producing a polynucleotide for use in single primer amplification | |
US5612199A (en) | Method for producing a polynucleotide for use in single primer amplification | |
US5804375A (en) | Reaction mixtures for detection of target nucleic acids | |
EP0519053B1 (en) | Nucleic acid amplification with dna-dependent rna polymerase activity of rna replicases | |
US5093245A (en) | Labeling by simultaneous ligation and restriction | |
US5728526A (en) | Method for analyzing a nucleotide sequence | |
CA2308368C (en) | Specific and sensitive nucleic acid detection method | |
JP2001512301A (en) | Internal positive control for nucleic acid amplification | |
EP1780292A1 (en) | Gene methylation assay controls | |
Gillespie | The magic and challenge of DNA probes as diagnostic reagents | |
JP4104657B2 (en) | Positive control for polynucleotide amplification | |
US20060257885A1 (en) | Homogeneous assay system | |
Smith-Zagone et al. | Molecular pathology methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB IT LI NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19891227 |
|
17Q | First examination report despatched |
Effective date: 19911212 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB IT LI NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19931020 Ref country code: BE Effective date: 19931020 Ref country code: AT Effective date: 19931020 |
|
REF | Corresponds to: |
Ref document number: 96180 Country of ref document: AT Date of ref document: 19931115 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3885027 Country of ref document: DE Date of ref document: 19931125 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2045127 Country of ref document: ES Kind code of ref document: T3 |
|
ITF | It: translation for a ep patent filed | ||
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 88306717.5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19980623 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19980707 Year of fee payment: 11 Ref country code: FR Payment date: 19980707 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19980720 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19980728 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19981012 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: SYNTEX (U.S.A.) INC. TRANSFER- BEHRINGWERKE AKTIEN Ref country code: CH Ref legal event code: PFA Free format text: BEHRING DIAGNOSTICS GMBH TRANSFER- DADE BEHRING MARBURG GMBH |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990721 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19990730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990731 Ref country code: FR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19990731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990731 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19990721 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed |
Ref document number: 88306717.5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000503 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20000810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050721 |